Page last updated: 2024-11-04

dextroamphetamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5826
CHEMBL ID612
CHEBI ID4469
SCHEMBL ID8859
MeSH IDM0006134

Synonyms (103)

Synonym
nsc126789
gtpl2147
s(+)amphetamine
dexamphetamine
dephadren
sympamin
amsustain
dexidrine
dextro-amphetamine
phenethylamine, alpha-methyl-, d-
einecs 200-112-1
dextroamphetamine [usan]
dexanfetamina [inn-spanish]
nsc 73713
dexamfetamina [inn-spanish]
desamfetamina
dexamphetaminum [inn-latin]
desamfetamina [dcit]
alpha-methylphenethylamine, d-form
dexamfetaminum [inn-latin]
phenethylamine, alpha-methyl-, (+)-
brn 2205872
d-1-phenyl-2-aminopropan [german]
hsdb 3055
CHEBI:4469 ,
(s)-alpha-methylbenzeneethanamine
(2s)-1-phenylpropan-2-amine
(alphas)-alpha-methylbenzeneethanamine
(+)-alpha-methylphenylethylamine
d-1-phenyl-2-aminopropane
(+)-amphetamine
(s)-(+)-amphetamine
nsc-73713
d-(s)-amphetamine
d-1-phenyl-2-aminopropan
d-2-amino-1-phenylpropane
d-am
(s)-amphetamine
PDSP1_001511
(s)-1-phenyl-2-propylamine
benzeneethanamine, alpha-methyl-, (alphas)-
(2s)-(+)-amphetamine
phenethylamine, alpha-methyl-, (+)- (8ci)
(+)-(s)-amphetamine
d-alpha-methylphenethylamine
(s)-alpha-phenylethylamine
(s)-(+)-beta-phenylisopropylamine
(s)-alpha-methylphenethylamine
(+)-alpha-methylphenethylamine
d-(+)-amphetamine
benzeneethanamine, alpha-methyl-, (s)-
dexadrine
benzeneethanamine, alpha-methyl-, (as)- (9ci)
(+)-phenaminum
(s)-1-phenyl-2-aminopropane
(s)-1-phenyl-2-propanamine
C07884
51-64-9
dextroamphetamine
dexamfetamine
d-amphetamine
DB01576
PDSP2_001495
xelstrym
CHEMBL612 ,
amphetamine, d-
amfetamine, (s)-
dextro amphetamine
d amphetamine
bdbm50022723
dexamfetamina
tz47u051fi ,
dexamfetaminum
dexamfetamine [inn]
dexanfetamina
amphetamine [dea]
dexamphetaminum
unii-tz47u051fi
4-12-00-02587 (beilstein handbook reference)
AB03711
dextroamphetamine [hsdb]
dextroamphetamine [mi]
dexamfetamine [who-dd]
dextroamphetamine [vandf]
EPITOPE ID:224549
SCHEMBL8859
(s)-1-phenylpropan-2-amine
KWTSXDURSIMDCE-QMMMGPOBSA-N
1we ,
AB01563181_01
DTXSID8022907 ,
(s)-(+)-amphetamine (dextroamphetamine) 1.0 mg/ml in methanol
dextroamphetamine; d-amphetamine; dexamphetamine; dexedrine; dextrostat
1-methyl-2-phenyl-ethylamine
Q1706418
51-64-9 (free base)
dexanfetamina (inn-spanish)
dexamfetaminum (inn-latin)
dexamphetaminum (inn-latin)
dtxcid802907
amphetamine (d)
dexamfetamina (inn-spanish)
beta-phenyl-iso-propyl amine

Research Excerpts

Overview

Dextroamphetamine (Dexedrine) is an effective fatigue countermeasure for use in military subject pilots.

ExcerptReferenceRelevance
"Dextroamphetamine (Dexedrine) is an effective fatigue countermeasure for use in military subject pilots who are deprived of sleep. "( Utility of dextroamphetamine for attenuating the impact of sleep deprivation in pilots.
Caldwell, JA; Caldwell, JL; Darlington, KK, 2003
)
2.15

Actions

ExcerptReferenceRelevance
"Dextroamphetamine tended to produce more compulsive behaviors, which were also more likely to resemble clinical obsessive-compulsive disorder (OCD), than did methylphenidate."( Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?
Amass, J; Borcherding, BG; Elia, J; Keysor, CS; Rapoport, JL, 1990
)
1

Treatment

Dextroamphetamine treatment substantially reduced the spinal fluid content of homovanillic acid but not of 5-hydroxyindoleacetic acid. Treatment with dextroamphetamine combined with physical therapy did not improve recovery of motor function.

ExcerptReferenceRelevance
"Dextroamphetamine treatment led to stabilization or reduction of BMI z-score in a cohort of 7 patients with hypothalamic obesity, with no adverse effects. "( Treatment of Hypothalamic Obesity with Dextroamphetamine: A Case Series.
Denzer, C; Denzer, F; Lennerz, BS; Lustig, RH; Vollbach, H; Wabitsch, M, 2019
)
2.23
"Dextroamphetamine treatment substantially reduced the spinal fluid content of homovanillic acid but not of 5-hydroxyindoleacetic acid."( Central monoamines and hyperkinase of childhood.
Chase, TN; Shetty, T, 1976
)
0.98
"Treatment with dextroamphetamine combined with physical therapy did not improve recovery of motor function compared with placebo combined with physical therapy as assessed 3 months after hemispheric ischemic stroke. "( Effect of Dextroamphetamine on Poststroke Motor Recovery: A Randomized Clinical Trial.
Dromerick, AW; Goldstein, LB; Good, DC; Lennihan, L; Pura, J; Rabadi, MJ; Reding, MJ; Samsa, GP, 2018
)
1.24

Toxicity

The side-effect profiles of dextroamphetamine and methylphenidate appeared similar at the group level. All drugs were given SC, in increasing doses until two animals had dystonia/other adverse effects (AE)

ExcerptReferenceRelevance
"The lethality of d-amphetamine was studied in isolated and aggregated mice with and without previous habituation to the physical or to the physical and social environment of chronically aggregated social condition under which the toxic effects of d-amphetamine were tested."( Influence of previous housing history on the toxicity of amphetamine in aggregate mice.
Carranza, J; García-Pineda, J; Ortega-Corona, BG; Salazar, LA; Vargas-Rivera, J; Villarreal, J,
)
0.13
"To compare the side effect profiles of methylphenidate (MPH) and dexamphetamine (DEX) in children with attention deficit hyperactivity disorder (ADHD), as well as to determine which symptoms are genuine adverse effects of stimulant medication, as opposed to aspects of the child's underlying behavioral phenotype."( Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
Barker, M; Efron, D; Jarman, F, 1997
)
0.3
" Overall, both MPH and DEX were well tolerated by most subjects, with only four subjects discontinuing the trial period because of severe adverse effects (2 -1."( Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial.
Barker, M; Efron, D; Jarman, F, 1997
)
0.3
" L-DOPA pretreatment did not significantly alter any of the toxic effects of the amphetamine."( Neurotoxic effects of amphetamine plus L-DOPA.
Halladay, AK; Myers, CS; Wagner, GC; Widmer, DA, 1999
)
0.3
"Neuroleptic primed Cebus apella monkeys have proven reliable in screening antipsychotics for extrapyramidal side effect (EPS) potential in humans, and the ratio EPS liability/antiamphetamine efficacy ["therapeutic index" (TI)] has fit well with clinical results."( New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
Gerlach, J; Peacock, L, 1999
)
0.3
" All drugs were given SC, in increasing doses until two animals had dystonia/other adverse effects (AE), and in decreasing doses with a fixed dose of dextroamphetamine producing motor unrest and stereotypies, to find the minimum significant antiamphetamine dose (AA)."( New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
Gerlach, J; Peacock, L, 1999
)
0.5
" DOD 647 up to 2 mg/kg had no adverse effects."( New and old antipsychotics versus clozapine in a monkey model: adverse effects and antiamphetamine effects.
Gerlach, J; Peacock, L, 1999
)
0.3
" Our data show that opioid drugs (heroin and morphine) are more toxic than stimulant drugs (d-amphetamine and cocaine)."( Toxic effects of opioid and stimulant drugs on undifferentiated PC12 cells.
Macedo, TR; Morgadinho, MT; Oliveira, CR; Oliveira, MT; Rego, AC, 2002
)
0.31
" Adverse events, blood pressure, heart rate, body temperature, consciousness level, and functional outcome measures were followed up daily during treatment."( Safety of dexamphetamine in acute ischemic stroke: a randomized, double-blind, controlled dose-escalation trial.
Martinsson, L; Wahlgren, NG, 2003
)
0.32
" There was no difference between dexamphetamine and placebo regarding adverse events, body temperature, or consciousness level."( Safety of dexamphetamine in acute ischemic stroke: a randomized, double-blind, controlled dose-escalation trial.
Martinsson, L; Wahlgren, NG, 2003
)
0.32
"Overall, dexamphetamine was safe and well tolerated by patients with acute cerebral ischemia, but blood pressure and heart rate increased during treatment in comparison to placebo."( Safety of dexamphetamine in acute ischemic stroke: a randomized, double-blind, controlled dose-escalation trial.
Martinsson, L; Wahlgren, NG, 2003
)
0.32
" Adverse events were monitored throughout the study."( Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants.
Feldman, NT; Fry, JM; Harsh, J; Schwartz, JR, 2003
)
0.32
" The most frequent adverse events were headache, nausea, and insomnia; the majority of adverse events were mild or moderate in nature."( Efficacy and safety of modafinil for improving daytime wakefulness in patients treated previously with psychostimulants.
Feldman, NT; Fry, JM; Harsh, J; Schwartz, JR, 2003
)
0.32
" Most adverse events were mild to moderate and occurred during the first 4 weeks."( Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
Childress, AC; Findling, RL; Krishnan, S; McGough, JJ, 2008
)
0.35
" These effects were not clinically significant and no unexpected or serious adverse events were observed."( Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.
Hays, LR; Rush, CR; Stoops, WW, 2009
)
0.35
" Adverse events were generally mild and included dry mouth, decreased appetite, and insomnia."( Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder.
Adler, LA; Biederman, J; Goodman, DW; Kollins, SH; Krishnan, S; Weisler, RH; Zhang, Y, 2008
)
0.35
" The most common adverse events reported with LDX were typical of amphetamine products and included decreased appetite, insomnia, upper abdominal pain, headache, irritability, weight loss, and nausea."( The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib, J, 2009
)
0.35
" Hepatocytes isolated from nifedipine-treated and control rats were incubated with D-amphetamine at a concentration of 100 micromol L(-1), which was determined to be an average toxic concentration (TC50) for the compound."( D-amphetamine toxicity in freshly isolated rat hepatocytes: a possible role of CYP3A.
Kondeva-Burdina, M; Mitcheva, M; Vitcheva, V, 2009
)
0.35
" Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, and electrocardiograms."( Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Findling, RL; Gao, J; Ginsberg, LD; Jain, R, 2009
)
0.35
" Safety assessments included adverse events inquiries, vital signs, and electrocardiograms while the primary effectiveness assessment was the ADHD Rating Scale (ADHD-RS) total score."( Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
Adler, L; Gao, J; Mattingly, G; Squires, L; Weisler, R; Young, J, 2009
)
0.35
" The most common treatment-emergent adverse events (TEAEs) were upper respiratory tract infection (21."( Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder.
Adler, L; Gao, J; Mattingly, G; Squires, L; Weisler, R; Young, J, 2009
)
0.35
" Safety assessments included adverse events."( Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Buckwalter, M; Ermer, J; Homolka, R; Martin, P; Purkayastha, J; Roesch, B, 2010
)
0.36
" Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, and electrocardiograms."( Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.
Brams, M; Gao, J; Gasior, M; Giblin, J; Squires, L; Wigal, T, 2010
)
0.36
" Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, physical examinations, and ECG."( Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Childress, AC; Cutler, AJ; Ferreira-Cornwell, MC; Findling, RL; Gasior, M; Hamdani, M; Squires, L, 2011
)
0.37
" Self-report rating scales of functioning and direct assessment of ADHD symptoms, verbal learning/memory, and adverse side effects were collected (baseline only for control students)."( Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD.
Carson, KM; Dupaul, GJ; O'Dell, SM; Rossi, JS; Swentosky, A; Verdi, G; Vilardo, BA; Weyandt, LL, 2012
)
0.38
"To evaluate the type, frequency, duration, and severity of treatment emergent adverse events (TEAEs) of the prodrug lisdexamfetamine dimesylate (LDX) in children with and without previous exposure to stimulant medication in the treatment of attention-deficit/hyperactivity disorder (ADHD)."( Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
Jun, A; Lerner, MA; Stehli, A; Steinberg-Epstein, R; Wigal, SB; Wong, AA, 2012
)
0.38
" Safety was assessed using adverse effects and LDX levels."( Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
Jun, A; Lerner, MA; Stehli, A; Steinberg-Epstein, R; Wigal, SB; Wong, AA, 2012
)
0.38
"LDX reduced the core symptoms of ADHD with more severe adverse events in stimulant-naïve than previous-exposure subjects."( Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
Jun, A; Lerner, MA; Stehli, A; Steinberg-Epstein, R; Wigal, SB; Wong, AA, 2012
)
0.38
" While medications for ADHD are generally well-tolerated, there are common, although less severe, as well as rare but severe adverse events AEs during treatment with ADHD drugs."( Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E, 2013
)
0.39
" Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, and electrocardiograms."( A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Childress, AC; Cutler, AJ; Ferreira-Cornwell, MC; Findling, RL; Gasior, M; Hamdani, M; Saylor, K, 2013
)
0.39
" Tolerability and safety were assessed by monitoring treatment-emergent adverse events (TEAEs), height and weight, vital signs and electrocardiogram parameters."( Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Anderson, CS; Bloomfield, R; Caballero, B; Cardo, E; Civil, R; Coghill, D; Dittmann, RW; Higgins, N; Hodgkins, P; Lyne, A; Nagy, P, 2013
)
0.39
"2% (53/88) receiving lisdexamfetamine dimesylate had ≥ 1 treatment-emergent adverse event, the most frequent with lisdexamfetamine dimesylate being dry mouth and headache (both 11."( A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
Cutler, AJ; Gao, J; Geibel, BB; Lasser, R; Patkar, AA; Richards, C; Sambunaris, A; Trivedi, MH, 2013
)
0.39
"The purpose of this study was to investigate whether the availability of both dextroamphetamine and methylphenidate provides an opportunity to minimize adverse events in a pediatric attention-deficit/hyperactivity disorder (ADHD) stimulant trial."( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Aabech, HS; Ramtvedt, BE; Sundet, K, 2014
)
0.83
" Barkley's Side-Effect Rating Scale (SERS), rated by parents, was used to assess adverse events."( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Aabech, HS; Ramtvedt, BE; Sundet, K, 2014
)
0.6
"The side-effect profiles of dextroamphetamine and methylphenidate appeared similar at the group level."( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Aabech, HS; Ramtvedt, BE; Sundet, K, 2014
)
0.9
"The availability of both dextroamphetamine and methylphenidate may contribute to minimize adverse events in a subsample of children in pediatric ADHD stimulant trials."( Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
Aabech, HS; Ramtvedt, BE; Sundet, K, 2014
)
0.91
"In short-term, parallel-group, placebo-controlled, phase III trials, treatment-emergent adverse events (TEAEs) in children, adolescents, and adults receiving LDX were typical for those reported for stimulants in general."( A systematic review of the safety of lisdexamfetamine dimesylate.
Caballero, B; Civil, R; Coghill, DR; Sorooshian, S, 2014
)
0.4
" Treatment-emergent adverse events (AEs) were reported by 4 participants receiving placebo and by 23 participants receiving LDX (all doses) with no serious AEs while on active treatment."( Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Corcoran, M; Dirks, B; Ermer, J; Gertsik, L; Martin, P; Raychaudhuri, A; Stevenson, A; Walling, D, 2014
)
0.4
" Safety assessments included treatment-emergent adverse events, vital signs, and change in weight."( Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.
Ferreira-Cornwell, MC; Gao, J; Gasior, M; Hudson, JI; Jonas, J; McElroy, SL; Mitchell, JE; Wang, J; Whitaker, T; Wilfley, D, 2015
)
0.42
" The incidence of any treatment-emergent adverse events was 58."( Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial.
Ferreira-Cornwell, MC; Gao, J; Gasior, M; Hudson, JI; Jonas, J; McElroy, SL; Mitchell, JE; Wang, J; Whitaker, T; Wilfley, D, 2015
)
0.42
" Safety assessments included physical examination, chemistry, hematology, vital signs, and treatment-emergent adverse events (TEAEs)."( The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study.
Brams, M; Childress, AC; Cutler, AJ; Kollins, SH; Northcutt, J; Padilla, A; Turnbow, JM, 2015
)
0.42
" Withdrawals due to all-cause, adverse effects and lack of efficacy were defined as primary outcomes evaluating the safety of such medications."( An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments.
Gao, J; He, S; Li, Y; Wang, Q; Zhang, Y, 2017
)
0.46

Pharmacokinetics

An open-label, randomized, crossover study was performed in healthy male volunteers to evaluate the potential pharmacokinetic and pharmacodynamic interactions and tolerability of single oral doses of modafinil and dextroamphetamine.

ExcerptReferenceRelevance
" An increase in pharmacodynamic changes on the descending slope of the kinetic curve resulted in a so-called 'hysteresis loop', the implication of which is discussed."( Objective measures in determining the central effectiveness of a new antihypoxidotic SL-76188: pharmaco-EEG, psychometric and pharmacokinetic analyses in the elderly.
Grünberger, J; Linzmayer, L; Saletu, B; Stöhr, H, 1982
)
0.26
"To establish whether the actions of D-amphetamine (Amp) and D-methamphetamine (MeAmp) on the striatal dopamine system were equipotent, pharmacokinetic profiles of each drug were applied to an analysis of their respective induced dopamine efflux profiles."( Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal.
Cho, AK; DiStefano, EW; Melega, WP; Schmitz, DA; Williams, AE, 1995
)
0.29
"An open-label, randomized, crossover study was performed in healthy male volunteers to evaluate the potential pharmacokinetic and pharmacodynamic interactions and tolerability of single oral doses of modafinil (200 mg) and dextroamphetamine (10 mg)."( Comparison of the single-dose pharmacokinetics and tolerability of modafinil and dextroamphetamine administered alone or in combination in healthy male volunteers.
Chen, Y; Eldon, R; Grebow, P; Hartman, L; Laughton, W; Markland, C; Simcoe, D; Wang, L; Wong, YN, 1998
)
0.71
" Characterization of the pharmacokinetic and/or pharmacodynamic behavior of operationally critical medications is crucial for their effective use in flight; as a first step, we sought to determine whether drugs administered in space actually reach the site of action at concentrations sufficient to elicit the therapeutic response."( Pharmacokinetic consequences of spaceflight.
Cintrón, NM; Putcha, L, 1991
)
0.28
" Samples for pharmacokinetic (PK) profiling were obtained on Days 21 and 28."( Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.53
"Assess the bioavailability of mixed amphetamine salts extended-release (MAS XR) 30-mg capsules and the dose proportionality of pharmacokinetic measures for MAS XR 20, 40, and 60 mg."( Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults.
Clausen, SB; Read, SC; Tulloch, SJ, 2005
)
0.33
"The extent of exposure as assessed by mean AUC0-24 and Cmax reflected the 3:1 ratio of d-amphetamine to l-amphetamine in MAS XR 30-mg capsules."( Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults.
Clausen, SB; Read, SC; Tulloch, SJ, 2005
)
0.33
" The method was successfully applied to pharmacokinetic study of the QAAMC in beagle dogs."( Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study.
Chen, Y; Fan, G; Lin, M; Wang, C; Wu, Y; Zhao, W, 2007
)
0.34
" Descriptive statistics were used for pharmacokinetic parameters."( Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers.
Krishnan, SM; Stark, JG, 2008
)
0.35
" Blood samples were collected predose and 0 to 96 hours postdose for pharmacokinetic analysis."( Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Buckwalter, M; Ermer, JC; Haffey, MB; Homolka, R; Lasseter, KC; Martin, P; Zhang, P, 2009
)
0.35
" h/mL, for Cmax and AUCinf, respectively."( Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Buckwalter, M; Ermer, JC; Haffey, MB; Homolka, R; Lasseter, KC; Martin, P; Zhang, P, 2009
)
0.35
" However, approximately 50% of subjects receiving MAS XR showed an earlier Tmax while on omeprazole, indicating unpredictable release of active drug by the second bead of MAS XR, most likely related to reduced stomach acid while on a PPI compromising the pulsed delivery of MAS XR."( Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
Buckwalter, M; Ermer, JC; Haffey, MB; Homolka, R; Lasseter, KC; Martin, P; Zhang, P, 2009
)
0.35
" Dose-proportionality and intersubject and intrasubject variability of pharmacokinetic parameters were examined."( Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers.
Buckwalter, M; Ermer, J; Homolka, R; Martin, P; Purkayastha, J; Roesch, B, 2010
)
0.36
" Information on the pharmacokinetic profile of LDX in children with ADHD is lacking."( Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover
Boellner, SW; Krishnan, S; Stark, JG; Zhang, Y, 2010
)
0.36
"The aim of this study was to assess the pharmacokinetic properties of d-amphetamine delivery from LDX, and intact LDX with increasing doses of LDX administered in children with ADHD."( Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover
Boellner, SW; Krishnan, S; Stark, JG; Zhang, Y, 2010
)
0.36
" The pharmacokinetic properties of d-amphetamine and intact LDX were calculated over 48 hours."( Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover
Boellner, SW; Krishnan, S; Stark, JG; Zhang, Y, 2010
)
0.36
"The accelerating rotarod test is a preclinical pharmacodynamic test to assess the effect of a treatment on an animal's motor coordination."( A latent pharmacokinetic time profile to model dose-response survival data.
Adriaan Bouwknecht, J; Bijnens, L; Jacobs, T; Molenberghs, G; Straetemans, R, 2010
)
0.36
"Data on pharmacokinetic parameters of the prodrug stimulant lisdexamfetamine dimesylate via alternate routes of administration are limited."( Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
Buckwalter, M; Dennis, K; Diehl, B; Doll, WJ; Ermer, JC; Haffey, MB; Martin, PT; Page, RC; Sandefer, EP, 2011
)
0.37
" Mean ± SD elimination half-life (t(1/2)) values were also similar for PO (11."( Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
Buckwalter, M; Dennis, K; Diehl, B; Doll, WJ; Ermer, JC; Haffey, MB; Martin, PT; Page, RC; Sandefer, EP, 2011
)
0.37
" Subject variability for d-amphetamine pharmacokinetic parameters was low."( Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men.
Buckwalter, M; Dennis, K; Diehl, B; Doll, WJ; Ermer, JC; Haffey, MB; Martin, PT; Page, RC; Sandefer, EP, 2011
)
0.37
"Among 80 enrolled subjects, 77 were included in pharmacokinetic and safety analyses."( An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults.
Corcoran, M; Ermer, J; Haffey, MB; Harlin, B; Lasseter, K; Martin, P; Purkayastha, J; Richards, C; Roesch, B, 2013
)
0.39
" However, the potential for pharmacokinetic drug-drug interactions (DDIs) between GXR and lisdexamfetamine dimesylate (LDX, Vyvanse®; Shire US LLC, Wayne, PA, USA) has not been thoroughly evaluated."( Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
Corcoran, ME; Ermer, J; Fetterolf, J; Haffey, M; Martin, P; Preston, P; Purkayastha, J; Roesch, B; Wang, P, 2013
)
0.39
" Following administration of LDX alone or in combination with GXR, the statistical comparisons of the AUC0-∞ and Cmax of d-amphetamine fell entirely within the reference interval."( Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
Corcoran, ME; Ermer, J; Fetterolf, J; Haffey, M; Martin, P; Preston, P; Purkayastha, J; Roesch, B; Wang, P, 2013
)
0.39
"In healthy adults, coadministration of GXR and LDX did not result in a clinically meaningful pharmacokinetic DDI compared with either treatment alone."( Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate.
Corcoran, ME; Ermer, J; Fetterolf, J; Haffey, M; Martin, P; Preston, P; Purkayastha, J; Roesch, B; Wang, P, 2013
)
0.39
" Furthermore, unlike d-amphetamine, the pharmacodynamic effects of LDX are independent of the route of administration underlining the requirement to be hydrolyzed by contact with red blood cells."( Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug.
Hutson, PH; Pennick, M; Secker, R, 2014
)
0.4
" Consistent with previous studies, pharmacokinetic parameters increased linearly with increasing LDX dose."( Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: a randomized, double-blind, placebo-controlled trial of ascending multiple doses.
Corcoran, M; Dirks, B; Ermer, J; Gertsik, L; Martin, P; Raychaudhuri, A; Stevenson, A; Walling, D, 2014
)
0.4
" Therefore, the purpose of this study was to determine the pharmacokinetics of oral dextroamphetamine in plasma and quantify the rate of deposition into hair in healthy adults using a linked population pharmacokinetic model."( A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults.
Cook, SF; Roberts, JK; Rollins, DE; Sherwin, CM; Stockmann, C; Wilkins, DG, 2015
)
0.91
" Pharmacokinetic end points included maximum plasma concentration (Cmax) and area under the plasma concentration versus time curve from time 0 to infinity (AUC0-∞) or to last assessment (AUClast)."( A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Corcoran, M; Ermer, J; Lasseter, K; Marbury, T; Martin, PT; Yan, B, 2016
)
0.43
"Mean LDX Cmax, AUClast, and AUC0-∞ in participants with mild to severe renal impairment did not differ from those with normal renal function; participants with ESRD had higher mean Cmax and AUClast than those with normal renal function."( A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function.
Corcoran, M; Ermer, J; Lasseter, K; Marbury, T; Martin, PT; Yan, B, 2016
)
0.43
" Clinical effects of LDX in attention-deficit/hyperactivity disorder (ADHD) have been shown to persist up to 14 hours; however, pharmacokinetic (PK) data of LDX and amphetamine in ADHD adults are not currently available."( Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler, LA; Alperin, S; Faraone, SV; Leon, T, 2017
)
0.46
" pharmacodynamic [PD])."( Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder.
Adler, LA; Alperin, S; Faraone, SV; Leon, T, 2017
)
0.46
" Parallel pharmacokinetic studies in the same monkeys determined plasma benzphetamine, d-methamphetamine and/or d-amphetamine levels for correlation with behavioral effects."( Role of d-amphetamine and d-methamphetamine as active metabolites of benzphetamine: Evidence from drug discrimination and pharmacokinetic studies in male rhesus monkeys.
Banks, ML; Fennell, TR; Negus, SS; Snyder, RW, 2017
)
0.46
" A semimechanistic pharmacokinetic and pharmacodynamic (PK/PD) model with consideration of these multiple effects as a basis was developed."( Development of a Semimechanistic Pharmacokinetic-Pharmacodynamic Model Describing Dextroamphetamine Exposure and Striatal Dopamine Response in Rats and Nonhuman Primates following a Single Dose of Dextroamphetamine.
Adhikari, S; Bhattacharya, C; Folgering, JH; Schlumbohm, C; Steinbach, D; Stratford, RE; van Gaalen, MM, 2019
)
0.74
"This is the first report of the pharmacodynamic (PD) effects of the selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446."( Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial.
de Boer, P; de Kam, M; Drevets, W; Jacobs, G; Kanhai, K; Ravenstijn, P; Recourt, K; Siebenga, P; Timmers, M; van der Aart, J; van Gerven, J; van Nueten, L; Zuiker, R, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" The effects of chlordiazepoxide on feeding parameters were generally additive with those of either d-amphetamine or fenfluramine, whenever chlordiazepoxide was given in combination with one of the anorectic drugs."( Feeding parameters with two food textures after chlordiazepoxide administration, alone or in combination with d-amphetamine or fenfluramine.
Cooper, SJ; Francis, RL, 1979
)
0.26
" Comparison of backward and long-delayed controls in a drug-drug procedure that used a taste aversion test revealed that both forward and delayed pairings can produce attenuated aversions in relation to a backward group regardless of whether the unconditional stimulus is amphetamine (Experiment 1) or lithium chloride (Experiment 2)."( Methodological issues in drug-drug conditioning in rats: nonassociative factors in heart rate and avfail.
Biederman, GB; Davey, VA, 1991
)
0.28
" The effects of cocaine alone and in combination with d-amphetamine, caffeine, morphine or delta-9-tetrahydrocannabinol were determined in five male white Carneaux pigeons responding under a multiple fixed-ratio 30, fixed-interval 600 schedule (mult FR FI)."( The effects of cocaine in combination with other drugs of abuse on schedule-controlled behavior in the pigeon.
Evans, EB; Wenger, GR, 1990
)
0.28
"A series of agents were tested for their ability to interact with the analgetic actions of either d-amphetamine (d-AMP) or l-amphetamine (l-AMP), or morphine in rats using the hot plate procedure."( Differential analgetic actions of amphetamine enantiomers in the mouse: a drug-drug interaction study.
Maickel, RP; Spratto, GR; Tocco, DR, 1985
)
0.27
" Additionally, d-amphetamine or naloxone was administered with Gbl to test hypotheses of Gbl's neurochemical mechanisms of action."( Gamma-butyrolactone's discriminability and effect on low rates of lever pressing by rats: alone and in combination with D-amphetamine and naloxone.
Cleary, J; McIntire, KD; Weinfurter, S, 1988
)
0.27
"The behavioral effects of phencyclidine (PCP) and ketamine administered alone and in combination with naloxone, atropine, methyl atropine, chlorpromazine and d-amphetamine were studied in squirrel monkeys trained to press a response lever under a fixed-ratio 30 schedule maintained by the termination of a stimulus associated with electric shock presentation."( Behavioral effects of phencyclidine and ketamine alone and in combination with other drugs.
Byrd, LD; Howell, LL; Standish, LJ, 1987
)
0.27
"Single doses of d-amphetamine, chlorpheniramine or diazepam were combined with ethanol under two conditions: (i) in drug-naive mice and (ii) in mice which had been given a single dose of ethanol 72 hr previously."( Drug interactions with ethanol. Effects on body temperature and motor impairment.
Maickel, RP; Nash, JF, 1986
)
0.27
" When phencyclidine was administered in combination with d-amphetamine, the phencyclidine dose-effect curves tended to shift to the left as the dose of d-amphetamine was increased."( Phencyclidine in combination with d-amphetamine: differential effects on acquisition and performance of response chains in monkeys.
Moerschbaecher, JM; Thompson, DM, 1984
)
0.27
" Often, these agents are used in combination with other medications."( Drug interactions with psychostimulants.
DeVane, CL; Markowitz, JS; Morrison, SD, 1999
)
0.3
"Glucose was tested alone or in combination with two stimulant drugs, amphetamine and nicotine, in mice of the CD-1 strain subjected to five daily shuttle-box training sessions."( Shuttle-box avoidance learning in mice: improvement by glucose combined with stimulant drugs.
Battaglia, M; Pavone, F; Sansone, M, 2000
)
0.31
"The potential for a drug-drug interaction between modafinil and dextroamphetamine, each at steady state, was investigated in an open-label, randomized, single-period studyin 32 healthy male and female volunteers."( Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.77
" This study intended to investigate the effect of an increased intensity of physiotherapy in combination with dexamphetamine the first week after ischemic stroke in patients with an impaired level of consciousness and severe motor dysfunction."( Intensive early physiotherapy combined with dexamphetamine treatment in severe stroke: a randomized, controlled pilot study.
Eksborg, S; Martinsson, L; Wahlgren, NG, 2003
)
0.32
"An increased intensity of physiotherapy in combination with dexamphetamine during the first week after stroke onset did not affect short- or long-term outcome in this limited sample of patients with severe stroke."( Intensive early physiotherapy combined with dexamphetamine treatment in severe stroke: a randomized, controlled pilot study.
Eksborg, S; Martinsson, L; Wahlgren, NG, 2003
)
0.32
" After acquiring the discrimination, the effects of cocaine (0, 25, 50, 100 and 200 mg) administered alone and in combination with aripiprazole (15 mg) were determined."( Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans.
Glaser, PE; Hays, LR; Lile, JA; Rush, CR; Stoops, WW, 2011
)
0.37
" In the present study, we have examined the effect of lisdexamfetamine dimesylate (LDX), an amphetamine pro-drug that is approved for the treatment of ADHD on acetylcholine and histamine efflux in pre-frontal cortex and hippocampus alone and in combination with the anti-depressant s-citalopram."( Effects of lisdexamfetamine alone and in combination with s-citalopram on acetylcholine and histamine efflux in the rat pre-frontal cortex and ventral hippocampus.
Folgering, JH; Heins, MS; Hutson, PH, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level."( Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Akpinar, S; Herrmann, WM; Itil, TM, 1975
)
0.25
" On the contrary, the [3H]mazindol tracer dose induced a marked labelling of the noradrenaline uptake complex in cerebellum; its prevention by desipramine (5 mg/kg) increased simultaneously the cerebral bioavailability and thereby the striatal labelling of the dopamine transporter."( Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice.
Bonnet, JJ; Costentin, J; Thibaut, F; Vaugeois, JM, 1996
)
0.29
" That spaceflight may alter bioavailability was proposed when drugs prescribed to alleviate space motion sickness (SMS) had little therapeutic effect."( Pharmacokinetic consequences of spaceflight.
Cintrón, NM; Putcha, L, 1991
)
0.28
" Relatively little has been reported about the bioavailability of methamphetamine when smoked or used intranasally."( The bioavailability of intranasal and smoked methamphetamine.
Boxenbaum, H; Everhart, ET; Harris, DS; Jones, RT; Mendelson, JE; Sequeira, G, 2003
)
0.32
" Plasma and urine concentrations were measured for calculation of bioavailability and other pharmacokinetic parameters by noncompartmental methods."( The bioavailability of intranasal and smoked methamphetamine.
Boxenbaum, H; Everhart, ET; Harris, DS; Jones, RT; Mendelson, JE; Sequeira, G, 2003
)
0.32
"Methamphetamine was well absorbed after smoking or intranasal administration, with bioavailabilities of 79% after intranasal administration and 67% of the estimated delivered dose or 37."( The bioavailability of intranasal and smoked methamphetamine.
Boxenbaum, H; Everhart, ET; Harris, DS; Jones, RT; Mendelson, JE; Sequeira, G, 2003
)
0.32
" However, limited peptide stability and oral bioavailability have prevented these compounds from being developed as relevant pharmaceuticals."( Design, synthesis, and evaluation of the antipsychotic potential of orally bioavailable neurotensin (8-13) analogues containing non-natural arginine and lysine residues.
Dix, TA; Hadden, MK; Kokko, KP; Mazella, J; Orwig, KS, 2005
)
0.33
"Assess the bioavailability of mixed amphetamine salts extended-release (MAS XR) 30-mg capsules and the dose proportionality of pharmacokinetic measures for MAS XR 20, 40, and 60 mg."( Single- and multiple-dose pharmacokinetics of an oral mixed amphetamine salts extended-release formulation in adults.
Clausen, SB; Read, SC; Tulloch, SJ, 2005
)
0.33
"The relative bioavailability of oral lisdexamfetamine dimesylate, a prodrug of d-amphetamine, and active d-amphetamine was assessed in an open-label, single-dose, 3-treatment, 3-period, randomized, crossover study in 18 healthy adult volunteers."( Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.
Krishnan, S; Zhang, Y, 2008
)
0.35
" We estimated bioavailability of four different oral formulations used by the NASA RGO physicians for the treatment of motion sickness."( Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine.
Boyd, JL; Du, B; Locke, JP; Putcha, L; Vaksman, Z, 2007
)
0.57
"2 was used to estimate dextroamphetamine oral absorption rate constant, apparent clearance and volume of distribution of the plasma compartment, the plasma to hair incorporation rate constant, and the apparent volume of distribution in the hair compartment."( A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults.
Cook, SF; Roberts, JK; Rollins, DE; Sherwin, CM; Stockmann, C; Wilkins, DG, 2015
)
0.99
"Relative bioavailability of D-amphetamine (the active moiety) did not differ across administrations, which suggests that emptying an LDX capsule into orange juice or yogurt and consuming it is an alternative to intact capsules."( Relative Bioavailabilities of Lisdexamfetamine Dimesylate and D-Amphetamine in Healthy Adults in an Open-Label, Randomized, Crossover Study After Mixing Lisdexamfetamine Dimesylate With Food or Drink.
Corcoran, M; Ermer, J; Lasseter, K; Martin, PT, 2016
)
0.43
"To evaluate the relative bioavailability of a single dose of amphetamine extended-release oral suspension (AMPH EROS) compared with a single dose of extended-release mixed amphetamine salts (ER MAS) in healthy, fasted adult subjects."( A single-dose, comparative bioavailability study comparing amphetamine extended-release oral suspension with extended-release mixed amphetamine salts capsules.
Bouhajib, M; Kando, JC; King, TR; Pardo, A; Rafla, E, 2022
)
0.72
" Relative bioavailability between the products was determined by a statistical comparison of the area under the curve and maximum concentration (Cmax) for d-amphetamine and l-amphetamine."( A single-dose, comparative bioavailability study comparing amphetamine extended-release oral suspension with extended-release mixed amphetamine salts capsules.
Bouhajib, M; Kando, JC; King, TR; Pardo, A; Rafla, E, 2022
)
0.72

Dosage Studied

Dextroamphetamine sulphate was found to be a significantly mutogenic agent. Administration of low-dose dextroamphetamine in this dosing regimen does not alter the steady-state pharmacokinetics of modafinil.

ExcerptRelevanceReference
" Dose-response curves for locomotor activity were also determined with morphine and methadone administered intraventricularly."( Interactions between narcotic analgesics and benzodiazepine derivatives on behavior in the mouse.
Davis, DC; Holtzman, SG; Shannon, HE, 1976
)
0.26
"In the course of examining the complete dose-response relationship for the behavioral effects of LSD in the cat, we discovered that, in addition to large increases in investigatory and hallucinatory-like responses, two behaviors, not previously reported, are emitted with a high probability under LSD."( Behavioral effects of LSD in the cat: proposal of an animal behavior model for studying the actions of hallucinogenic drugs.
Jacobs, BL; Stern, WC; Trulson, ME, 1977
)
0.26
" Dose-response and time-effect curves were determined for morphine (1."( Dose- and time-dependent effects of narcotic analgesics on intracranial self-stimulation in the rat.
Holtzman, SG; Schaefer, GJ, 1977
)
0.26
"The dose-response relationship for d-amphetamine (0."( Actions and interactions of amphetamine on self-stimulation in rats.
Aulakh, CS; Pradhan, SN, 1979
)
0.26
" SHPGE2, PGE2, and C did not cause catalepsy and did not show statistically significant dose-response antagonism of rotational behavior at less than toxic doses."( Neuropharmacological and behavioral evaluation of prostaglandin E2 and 11-thiol-11-desoxy prostaglandin E2 in the mouse and rat.
Bloss, JL; Singer, GH, 1978
)
0.26
" Thus, as dosage increased performance tended towards a constant high rate of responding on the right-hand lever throughout a session, with a much lower response rate on the left-hand lever."( Effects of d-amphetamine on temporal and spatial discrimination in rats.
Sanger, DJ, 1978
)
0.26
" d-Amphetamine was given for three weeks in increasing dosage (2."( d-Amphetamine in elderly patients refractory to rehabilitation procedures.
Clark, AN; Mankikar, GD, 1979
)
0.26
" Dose-response curves were determined for chlorpromazine (0."( Failure of naloxone to modify the effects of chlorpromazine and d-amphetamine on avoidance behavior in the squirrel monkey.
Holtzman, SG, 1979
)
0.26
"The effect of various antipsychotic drugs on the blockade of dopaminergic receptors in striatum and limbic forebrain was examined by establishing dose-response curves for the increase in HVA and for the antagonism of d-amphetamine-induced rotation in rats with unilateral lesions of the substantia nigra."( On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain.
Dingell, JV; Hill, H; Robinson, SE; Setler, P; Stawarz, RJ; Sulser, F, 1975
)
0.25
" At the dosage and frequency of the test, dextroamphetamine sulphate was found to be a significantly mutogenic agent."( Mutagenicity obtained experimentally by oral administration of dextroamphetamine sulphate to the rat.
Aponte, N; Briceño, E; Lárez, A; Montenegro, M; Ochoa, Y,
)
0.64
" As evidenced by a shift in the dose-response curve measuring number of responses and number of reinforcements per session, this tolerance persisted for at least three months after cessation of the multiple drug injection regimen."( Long-term behavioral changes in the rhesus monkey after multiple daily injections of d-methylamphetamine.
Fischman, MW; Schuster, CR, 1977
)
0.26
"The effects of d-amphetamine dosage (0, 1, 3, and 5 mg/kg) and shock intensity (0."( Passive avoidance learning in the rat as functions of d-amphetamine dosage and shock intensity.
Seliger, DL, 1977
)
0.26
" Dose-response related decrements in male sexual behavior were observed following chlorpromazine and chlordiazepoxide."( Effects of chlordiazepoxide, oxazepam, chlorpromazine, and d-amphetamine on sexual responses in male and female hamsters.
Carter, CS; Daily, RF; Leaf, R, 1977
)
0.26
" This temporary effect on growth is present during the first few years of treatment and seems related to drug dosage and to the presence or absence of drug holidays."( The effects of stimulant medication on the growth of hyperkinetic children.
Hung, W; Lipman, RS; Overall, JE; Roche, AF, 1979
)
0.26
"A dose-response analysis was performed on D-amphetamine- and methylphenidate-induced changes in neuronal activity in the neostriatum of immobilized, phenidate-induced changes in neuronal activity in the neostriatum of immobilized, locally anesthetized rats."( Dose-dependent biphasic alterations in the spontaneous activity of neurons in the rat neostriatum produced by d-amphetamine and methylphenidate.
Rebec, GV; Segal, DS, 1978
)
0.26
" Dose-response curves and ED50 values were then determined in brief test sessions when no responses were reinforced."( Comparison of the discriminative stimulus properties of cocaine and amphetamine in rats.
D'Mello, GD; Stolerman, IP, 1977
)
0.26
" Dose-response relationships and time course of this effect for the various drugs were determined."( Effects of mazindol, fenfluramine and chlorimipramine on the 5-hydroxytryptamine uptake and storage mechanisms in rat brain: similarities and differences.
Carruba, MO; Mantegazza, P; Picotti, GB; Zambotti, F, 1977
)
0.26
" Total daily drug intake was related to the unit dose delivered per injection in that a higher drug dosage led to more drug intake."( Intravenous self-administration of drugs in rats.
de Wied, D; Slangen, JL; van Ree, JM, 1978
)
0.26
" Both blocking agents exert their effects on H--S following dose-response curves which are similar, whatever the drug used to evoke head-shaking."( Blockade of both pilocarpine and amphetamine-induced head-shaking with dopamine receptor antagonists.
Dem, B; Holmgren, B; Urbá-Holmgren, R, 1978
)
0.26
" A comparison of dose-response functions for dopamine using solution injections in VAS and posterior striatum (PS) confirmed that only VAS was responsive."( Identification of a subregion within rat neostriatum for the dopaminergic modulation of lateral hypothalamic self-stimulation.
Gold, MS; Neill, DB; Peay, LA, 1978
)
0.26
" A comparison of dose-response functions for injections of dopamine in solution into ventral anterior, central and posterior striatum confirmed that only injections into ventral anterior striatum (VAS) decreased response efficiency on the DRL schedule."( Anatomical specificity within rat striatum for the dopaminergic modulation of DRL responding and activity.
Herndon, JG; Neill, DB, 1978
)
0.26
"The time-course and the dose-response relationship for the antagonistic effect of alpha-methyl-p-tyrosine methyl ester HCl H 44/68 (alpha-MT) on d-amphetamine (10."( The relationship between amphetamine antagonism and depletion of brain catecholamines by alpha-methyl-p-tyrosine in rats.
Lewander, T; Widerlöv, E, 1978
)
0.26
" Aging shifted the pentobarbital dose-response curve to the left in both control and lead-treated animals and flattened interresponse time (IRT) distributions."( Effects of lead on temporally-spaced responding in rats.
Dietz, DD; Grant, LD; Kimmel, CA; McMillan, DE, 1978
)
0.26
", circling behavior) in a spherical "rotometer" and dose-response relationships were generated using d-amphetamine, apomorphine, L-Dopa, haloperidol, and scopolamine."( Drug-induced rotation in rats without lesions: behavioral and neurochemical indices of a normal asymmetry in nigro-striatal function.
Glick, SD; Jerussi, TP, 1976
)
0.26
" Dose-response analyses of the effects of d-amphetamine, an indirectly acting dopamine agonist, and apomorphine, a directly acting dopamine agonist, revealed a shift in the dose-response curves following chronic morphine treatment, indicating that the animals were supersensitive to these agents."( Alterations in the effects of dopamine agonists and antagonists on general activity in rats following chronic morphine treatment.
Overstreet, DH; Smee, ML, 1976
)
0.26
" No increase in food intake was revealed under any dosage or temperature condition."( Interaction effects of d-amphetamine treatment and ambient temperature on rat's food intake.
Yehuda, S, 1976
)
0.26
" Food and water consumption were dramatically reduced by each test drug at feeding periods immediately following and in some instances up to 4 days after dosing in all 3 groups."( Comparative effects of various naturally occurring cannabinoids on food, sucrose and water consumption by rats.
Knobloch, LC; Sofia, RD, 1976
)
0.26
" Dose-response curves were determined for the effects of morphine (0."( Comparison of the effects of morphine, pentazocine, cyclazocine and amphetamine on intracranial self-stimulation in the rat.
Holtzman, SG, 1976
)
0.26
" No correlations were found between dosage level and changes in weight and height percentiles."( Growth of hyperkinetic children taking methylphenidate, dextroamphetamine, or imipramine/desipramine.
Gross, MD, 1976
)
0.5
" Making water available before the session lowered the amphetamine dose-response curve along the vertical axis, suggesting that amphetamine did not mimic satiation."( Interresponse time changes as a function of water deprivation and amphetamine.
Brown, BM; Seiden, LS, 1975
)
0.25
" Second, dose-response relationships were established for the amphetamine enantiomers."( Differences between (+)- and (-)-amphetamine in effects on locomotor activity and L-dopa potentiating action in mice.
Strömberg, U; Svensson, TH, 1975
)
0.25
"The dose-response relationships for three stimulants have been explored."( The effects of age and illumination on the dose-response curves for three stimulants.
Isaac, W; Kallman, WM, 1975
)
0.25
" Prolonged pretreatment with suprathreshold doses of amphetamine decreased the threshold dosage of both amphetamine and apomorphine necessary to elicit stereotyped behavior."( Effect of chronic amphetamine exposure on stereotyped behavior: implications for pathogenesis of l-dopa-induced dyskinesias.
Crossett, P; Dana, N; Klawans, HL, 1975
)
0.25
"Pretreatment of rats with a dosage regimen of alphaMT that has no effect on the anorectic action of a single dose of 2 mg/kg of d-amphetamine or methamphetamine causes a marked reduction in the rate of continuous avoidance responding evoked by that same dose."( Differential effects of alphaMT on anorectic and stimulatory action of amphetamines.
Cox, RH; Maickel, RP, 1975
)
0.25
" Both measures indicated dose-response effects on responding; animals under either low or high doses of d-amphetamine made significantly less errors and took significantly fewer trials to learn the response than did middle dosage animals."( Dose-response effects of d-amphetamine on passive avoidance learning in the rat.
Seliger, DL, 1975
)
0.25
" Incremental doses of amphetamine and pilocarpine correspondingly suppressed PhAD parameters in a dose-response fashion."( Pharmacological suppression of photically evoked after-discharges in rats: incremental dose, hippocampal EEG and behavioral activity correlates.
Bigler, ED; Fleming, DE, 1976
)
0.26
" Cumulative dose-response curves to D-amphetamine were constructed in separate groups on day 6 or day 8 (0."( Effects of naloxone infusion upon spontaneous and amphetamine-induced activity.
Holtzman, SG; Jones, DN, 1992
)
0.28
" However, in rats trained on caffeine, PPA had no effect on the dose-response relationship for caffeine; similarly, in rats trained on PPA, caffeine had no effect on the dose-response relationship for PPA (no synergism or antagonism)."( Drug discrimination studies in rats with caffeine and phenylpropanolamine administered separately and as mixtures.
Mariathasan, EA; Stolerman, IP, 1992
)
0.28
" Under test conditions, doses lower than the training dose typically result in proportional decreases in D-amphetamine-appropriate responding, that is, dose-response curve is obtained."( [Discriminative stimulus properties of D-amphetamine: a neuropharmacological review].
Inagawa, K, 1992
)
0.28
" Results indicate ethanol induced decrements in performance of the skills necessary to drive an automobile were significantly decreased by dextroamphetamine in a dose-response fashion."( Interaction between ethanol and dextroamphetamine: effects on psychomotor performance.
Hicks, RE; McDonald, SA; Perez-Reyes, M; White, WR, 1992
)
0.77
" In the latter assay, both enantiomers of 6 had identical potencies, but their dose-response curves were not parallel."( Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
Frescas, SP; Johnson, MP; Nichols, DE; Oberlender, R, 1991
)
0.28
" Sprague-Dawley male rats (250-300 g) were dosed orally with aspartame (500 or 1000 mg/kg), phenylalanine (281 or 562 mg/kg), or tyrosine (309 or 618 mg/kg), and their behavior was analyzed 1 hr after dosing."( No change in spontaneous behavior of rats after acute oral doses of aspartame, phenylalanine, and tyrosine.
Kernan, WJ; Mullenix, PJ; Schunior, A; Tassinari, MS, 1991
)
0.28
" In the presence of a constant dose of prazosin, the dose-response curve for induction of rotation by AMPH was shifted to the right."( Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists.
Colpaert, FC; Mavridis, M; Millan, MJ, 1991
)
0.28
" Determination of the pentobarbital dose-response curve under the fixed-ratio component resulted in a steep curve characterized by responding on the saline lever at low doses and on the drug lever at higher doses."( Effects of schedule of reinforcement on a pentobarbital discrimination in rats.
McMillan, DE; Snodgrass, SH, 1991
)
0.28
" Drug interactions were studied by redetermining the cocaine dose-response curve in the presence of various fixed doses of the other drugs."( The effects of cocaine in combination with other drugs of abuse on schedule-controlled behavior in the pigeon.
Evans, EB; Wenger, GR, 1990
)
0.28
" MDMA resulted in a monotonic dose-response curve for activity but exhibited a biphasic dose response in ht and hm."( Application of entropy measures derived from the ergodic theory of dynamical systems to rat locomotor behavior.
Geyer, MA; Gold, LH; Mandell, AJ; Paulus, MP, 1990
)
0.28
" The dose-response curve for amphetamine was shifted downward and to the right by reserpine but was flattened by AMPT."( Depletion of catecholamines in the brain of rats differentially affects stimulation of locomotor activity by caffeine, D-amphetamine, and methylphenidate.
Finn, IB; Holtzman, SG; Iuvone, PM, 1990
)
0.28
" Generalization testing then followed in which dose-response curves were determined for the following drugs: d-amphetamine (3."( Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans.
Heishman, SJ; Henningfield, JE, 1991
)
0.28
" Single and combined dose-response results of rat locomotor activity are expressed as three-dimensional models."( Mapping and interpreting complex interactions between psychoactive drugs by simple computer-generated models.
Davies, C; Hughes, MJ; Steinberg, H; Sykes, EA, 1990
)
0.28
") 20 min before cocaine resulted in a 4- to 8-fold parallel shift to the right in the cocaine dose-response function."( Pharmacological characterization of the discriminative stimulus effects of cocaine in rhesus monkeys.
Anthony, EW; Kleven, MS; Woolverton, WL, 1990
)
0.28
" Oral self-administered d-amphetamine in a dosage of 3-4 mg/kg/day or 7-8 mg/kg/day significantly increased the running speed in a dose-dependent manner."( Learning abilities of rats in multiple T-mazes of two degrees of complexity under the influence of d-amphetamine.
Coper, H; Jänicke, B; Jänicke, UA; Schulze, G, 1990
)
0.28
" Complete dose-response functions for amphetamine and fenfluramine were determined before, during and after a period of repeated administration of each drug."( Differential development of tolerance to the effects of d-amphetamine and fenfluramine on food intake in baboons.
Foltin, RW, 1990
)
0.28
" The first established a dose-response function for the stereotypy and the second showed that experience with the apparatus prior to drug administration disrupted the stereotypy."( Previous experience disrupts d-amphetamine-induced stereotypic diving in rats.
DeVietti, TL; Petree, AD, 1989
)
0.28
" During experimental sessions, active drug or placebo was administered using an acute or divided dosing procedure."( Effect of d-amphetamine, secobarbital, and marijuana on choice behavior: social versus nonsocial options.
Heishman, SJ; Stitzer, ML, 1989
)
0.28
" Dosage may be crucial; 8 Efamol capsules per day were used in this study."( Gamma-linolenic acid for attention-deficit hyperactivity disorder: placebo-controlled comparison to D-amphetamine.
Arnold, LE; Kleykamp, D; Kontras, SB; Taylor, WA; Tobin, K; Votolato, NA, 1989
)
0.28
" Yohimbine caused about a 30 fold shift to the right in the dose-response curve whereas idazoxan almost completely abolished the mydriatic response to (+)-Amp."( Mechanism of dexamphetamine-induced mydriasis in the anaesthetized rat.
Hey, JA; Ito, T; Koss, MC, 1989
)
0.28
" Once criterion performance was attained, each group was tested with various doses of the drug used in their training, thus allowing for calculations of dose-response curves and ED50 values."( Stability of the stimulus properties of drugs over time.
Boja, JW; Schechter, MD; Signs, SA, 1989
)
0.28
" Chlorpromazine caused a slight shift in the dose-response curves as did chlordiazepoxide when used with phencyclidine."( Quantitative electrocortical changes in the rat induced by phencyclidine and other stimulants.
Bond, A; Neal, H, 1985
)
0.27
" Pharmacologically specific results were obtained rapidly and reliably, using a cumulative dosing procedure."( A simple and rapid method for assessing similarities among directly observable behavioral effects of drugs: PCP-like effects of 2-amino-5-phosphonovalerate in rats.
Koek, W; Ornstein, P; Woods, JH, 1987
)
0.27
" All three antihistaminics, at some dosage levels, enhanced morphine-induced hyperactivity, but did not change or even reduce locomotor stimulation induced by amphetamine and scopolamine."( Antihistaminics enhance morphine-, but not amphetamine- and scopolamine-induced hyperactivity in mice.
D'Udine, B; Renzi, P; Sansone, M; Vetulani, J, 1987
)
0.27
" Dose-response quantitative generalization was obtained by using 1 and 2 micrograms/kg caerulein."( Neuroleptic-like properties of cholecystokinin analogs: distinctive mechanisms underlying similar behavioral profiles depending on the route of administration.
De Witte, P; Gewiss, M; Roques, B; Vanderhaeghen, JJ,
)
0.13
" After determination of these dose-response relationships, the rats were divided into two groups."( Effects of central dopamine depletion on the d-amphetamine discriminative stimulus in rats.
Cervo, L; Woolverton, WL, 1986
)
0.27
" Maternal weight gained during the dosing period was decreased in a dose-related manner, but there were no dose-related differences in offspring body weights."( Early neurobehavioral and neurochemical alterations in rats prenatally exposed to imipramine.
Ali, SF; Buelke-Sam, J; Newport, GD; Slikker, W, 1986
)
0.27
" Lithium by itself in acute (2 meq kg-1, 24 and 4 h before test) or extended (2 meq kg-1 daily for 9 days) dosage had little effect on horizontal or vertical activity or levels of DA or DOPAC."( Hyperactivity induced by dexamphetamine/chlordiazepoxide mixtures in rats and its attenuation by lithium pretreatment: a role for dopamine?
Aylmer, CG; Steinberg, H; Webster, RA, 1987
)
0.27
" The dose-response curves for methylphenidate and d-amphetamine appeared to be quantal in nature."( Effects of chronic amphetamine in BALB/cBy mice, a strain that is not stimulated by acute administration of amphetamine.
Cao, W; Carney, JM; Logan, L; Seale, TW, 1988
)
0.27
" The results obtained by dosage of d-amphetamine, fenfluramine or mazindol, on days 5 and 8 after tumor implantation, failed to demonstrate conclusively any predominant modification of a dopaminergic, noradrenergic, or serotonergic system in the anorectic effects of these agents."( Effects of anorectic agents in rats bearing the Walker-256 tumor.
Johnson, K; Kinney, DR; Maickel, RP, 1987
)
0.27
" The medication trials were double-blind, placebo-controlled, dose-response studies."( Treatment of chronic closed head injury with psychostimulant drugs: a controlled case study and an appropriate evaluation procedure.
Evans, RW; Gualtieri, CT; Patterson, D, 1987
)
0.27
" Under conditions of such high aggression, the previously reported pro-aggressive action of a low (5 mg/kg) dosage of chlordiazepoxide (CDP) is hardly detectable."( Maternal aggression towards different sized male opponents: effect of chlordiazepoxide treatment of the mothers and d-amphetamine treatment of the intruders.
Mos, J; Olivier, B; van Oorschot, R, 1987
)
0.27
" Dose-response functions for stimulus control and response rate were determined for pentobarbital alone and in combination with selected doses of d-amphetamine or ethanol."( Differential modification of pentobarbital stimulus control by d-amphetamine and ethanol.
Kline, FS; Young, AM, 1986
)
0.27
" Thus, it appeared that the effect of food deprivation was to shift the amphetamine dose-response curve to the right."( Effect of amphetamine on sucrose-reinforced lever pressing: interaction with food deprivation.
Samson, HH, 1986
)
0.27
" The present experiments extend these findings by providing dose-response data on the effects of scopolamine and Ditran on neocortical activity in relation to behavior in the rat."( Joint cholinergic-serotonergic control of neocortical and hippocampal electrical activity in relation to behavior: effects of scopolamine, ditran, trifluoperazine and amphetamine.
Stewart, DJ; Vanderwolf, CH, 1986
)
0.27
" Several experiments were conducted to permit the selection and verification of dosage levels of d-amphetamine sulfate and methylmercuric chloride to be used in the CBTS."( Collaborative Behavioral Teratology Study: preliminary research.
Adams, J; Buelke-Sam, J; Kimmel, CA; Miller, DR; Nelson, CJ,
)
0.13
" As a follow-up to the Collaborative Behavioral Teratology Study, 3 experiments have been conducted at the NCTR to examine the behavioral teratogenicity of this compound following SC dosing on days 12-15 of gestation."( d-Amphetamine as a behavioral teratogen: effects depend on dose, sex, age and task.
Adams, J; Buelke-Sam, J; Gough, B; Holson, R; Kimmel, CA,
)
0.13
" Behavioral testing, 2 days to 4 mo post-treatment, indicated that DMSO and/or 50 mg/kg of BPAU retarded habituation of spontaneous exploratory activity, impaired acquisition of conditioned (auto-shaped) behavior, and changed the dose-response relationship ford-amphetamine-induced suppression of operant (fixed ratio 32) responding."( Long lasting behavioral effects of dimethyl sulfoxide and the "peripheral" toxicant p-bromophenylacetylurea.
Fossom, LH; Messing, RB; Sparber, SB, 1985
)
0.27
" The dose-response curves for D-amphetamine (1."( Acute exposure to triethyl lead enhances the behavioral effects of dopaminergic agonists: involvement of brain dopamine in organolead neurotoxicity.
Dehaven, DL; Schulz, DW; Tilson, HA; Walsh, TJ, 1986
)
0.27
" These results indicate the complexity of the AMPH dose-response effects upon measurable behaviors, the alteration in the duration of these effects as a function of the hormonal condition of the male rat, and the importance of examining discrete components of behavior when hormone-amphetamine interactions are examined."( The effect of hormonal condition on dose-dependent amphetamine-stimulated behaviors in the male rat.
Dluzen, DE; Green, MA; Ramirez, VD, 1986
)
0.27
" These results provide evidence that tolerance for cocaine used as a discriminative stimulus occurs as a function of chronic dose, dosing regimen and class of drug administered."( Characteristics of tolerance, recovery from tolerance and cross-tolerance for cocaine used as a discriminative stimulus.
Emmett-Oglesby, MW; Wood, DM, 1986
)
0.27
" The degree of drug tolerance was assessed by determining cumulative dose-response functions for morphine before, during and after chronic administration."( Modification of morphine tolerance by behavioral variables.
Sannerud, CA; Young, AM, 1986
)
0.27
" The ED50s of the effective neuroleptics for this inhibition were similar to those reported for antagonism of amphetamine-induced stereotypic behavior in the rat and the slopes of the dose-response curves were parallel indicating a common site and mechanism of action, presumably blockade of postsynaptic dopaminergic receptors."( Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination.
Schechter, MD, 1980
)
0.26
" A dose-response analysis of the effect of methylphenidate revealed no differences among the dietary groups."( Effect of dietary lipid on locomotor activity and response to psychomotor stimulants.
Brenneman, DE; Rutledge, CO, 1982
)
0.26
" The dosage of urinary MHPG seems to be a valuable index for the choice of the drug."( [Therapeutic implications of the biochemical features about depressive illness (author's transl)].
Lôo, H, 1981
)
0.26
" Comparisons were made on the basis of dose-response relationships."( Anorexia and hyperphagia produced by five pharmacologic classes of hallucinogens.
Morton, EC; Vaupel, DB, 1982
)
0.26
" This dosage of haloperidol had no effect on tactile placing in normal cats."( Amphetamine and apomorphine restore tactile placing after motor cortex injury in the cat.
Feeney, DM; Hovda, DA, 1983
)
0.27
" There was a difference in the pattern of dose-response effects."( Differential dose-response effects of dexamphetamine sulphate on hunger, arousal and mood in human volunteers.
Silverstone, T; Trenchard, E; Wells, B, 1983
)
0.27
" The interaction of these compounds was determined by repeated determination of the dose-response function for d-amphetamine in combination with different doses of haloperidol."( The effect of d-amphetamine and haloperidol alone and in combination on milk drinking in rats.
Foltin, RW; Schuster, CR; Woolverton, WL, 1983
)
0.27
" To determine if para-chlorophenylalanine (PCPA), which alters the pattern of the behavioral response to amphetamine, also changes the pattern of the neuronal response to the drug, a dose-response analysis was performed on amphetamine-induced changes in unit activity in the anterior neostriatum of rats pretreated 48 h previously with 300 mg/kg PCPA or vehicle."( Apparent serotonergic modulation of the dose-dependent biphasic response of neostriatal neurons produced by D-amphetamine.
Alloway, KD; Curtis, SD; Rebec, GV, 1981
)
0.26
" For both of these treatment regimens, the dose-response curves for AMP and APO induced suppression were shifted approximately 4-fold to the right of control."( Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic D-amphetamine treatment.
Wang, RY; White, FJ, 1984
)
0.27
" A nutmeg dosage devoid of action on motility was chosen for short-term administration to mice."( Effect of nutmeg on ethanol and d-amphetamine-produced alteration of locomotor activity in the mouse.
Messiha, FS; Zaki, NN, 1984
)
0.27
" A bell-shaped dose-response curve was found for D-Ala4-DSIP; for DSIP two active dose ranges were observed."( DSIP reduces amphetamine-induced hyperthermia in mice.
Coy, DH; Graf, MV; Kastin, AJ; Zadina, JE, 1984
)
0.27
" Control by injection was established, and dose-response curves resembled that obtained under two- or three- key choice training procedures."( d-Amphetamine discrimination established under a conditional discrimination procedure in pigeons.
Watanabe, S, 1983
)
0.27
" d-Amphetamine, cocaine, and caffeine each had the effect of elevating both bite and lever press responses; nicotine, chlorpromazine, chlordiazepoxide, and diazepam each elevated lever press responding while depressing bite responding across a portion of the dosage range; phenobarbital, alcohol, and morphine had the effect of depressing both bite and lever press responses but lever pressing was selectively more depressed than biting."( Unique influences of ten drugs upon post-shock biting attack and pre-shock manual responding.
Emley, GS; Hutchinson, RR, 1983
)
0.27
"Using measures of stereotypy such as rearing, licking, and chewing, low dosage administration of amphetamine can be shown to produce increased stereotypy over a period of days."( Short term augmentation of amphetamine-induced rotation bias.
Albrecht, JW; Elias, JW; Graff, R; Smith, CJ; Yandell, LR, 1983
)
0.27
" One subject who was administered dextroamphetamine did not produce a wave consistent with amphetamine with a dosage of 5 mg."( Qualitative measurement of drugs.
Gilbert, LM; Golz, A; Komorowski, FS; Westerman, ST, 1984
)
0.55
" In addition to these salient features, the results of this study also have an impact on stimulus specificity, and further emphasize the importance of thorough dose-response relationships as related to tests of stimulus generalization."( MDA: a psychoactive agent with dual stimulus effects.
Glennon, RA; Young, R, 1984
)
0.27
" Active compounds exhibited an inverted U-shaped dose-response curve."( Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
Butler, DE; L'Italien, YJ; Marriott, JG; Nordin, IC; Poschel, PH; Zweisler, L, 1984
)
0.27
" Dose-response functions for d-amphetamine were determined before and after conditions of chronic treatment."( Task-specific tolerance to d-amphetamine.
Emmett-Oglesby, MW; Lal, H; Spencer, DG; Wood, DM, 1984
)
0.27
" This was reflected behaviorally by an improvement in concentration, attention variability, complex reaction and mood, especially in the higher dosage range."( Objective measures in determining the central effectiveness of a new antihypoxidotic SL-76188: pharmaco-EEG, psychometric and pharmacokinetic analyses in the elderly.
Grünberger, J; Linzmayer, L; Saletu, B; Stöhr, H, 1982
)
0.26
" The effects of apomorphine resembled those of dexamphetamine, but whereas those of the latter were antagonized by less than equimolar dosage of methysergide, the effects of apomorphine were not; spiperone, effective against apomorphine, in equimolar dosage did not prevent the effects of dexamphetamine in 3 of 4 chickens tested."( Antipodal central effects of apomorphine and dopamine in chickens.
Koc, BA; Marley, E, 1982
)
0.26
" Chronically, the dose-response relationships were monotonic and the maximal effect was increased, suggesting that differential tolerance occurs to the sedative, but not to the anxiolytic, effects of this drug."( Hyponeophagia and arousal in rats: effects of diazepam, 5-methoxy-N,N-dimethyltryptamine, d-amphetamine and food deprivation.
Broadhurst, PL; Shephard, RA, 1982
)
0.26
" Repeated daily doses of 5 mg/kg for 2 weeks had no effects unless the dosage was progressively increased to toxic levels of 15 mg/kg over a 3-week period."( Comparative effects of acute and chronic administration of amphetamine on local cerebral glucose utilization in the conscious rat.
Dow-Edwards, D; Jehle, J; Kennedy, C; Orzi, F; Sokoloff, L, 1983
)
0.27
" Dose-response curves for d-amphetamine, pentobarbital, chlordiazepoxide, ethanol, morphine, phencyclidine and delta 9-tetrahydrocannabinol were determined."( Tolerance to d-amphetamine and lack of cross-tolerance to other drugs in rats under a multiple schedule of food presentation.
Brocco, MJ; McMillan, DE, 1983
)
0.27
" A series of dose-response functions were then determined by giving a dose of a drug or a pair of drug doses once every 4 days."( Effects of psychomotor stimulants, alone and in pairs, on milk drinking in the rat after intraperitoneal and intragastric administration.
Foltin, RW; Schuster, CR; Woolverton, WL, 1983
)
0.27
" Dose-response curves were determined for caffeine (6."( Complete, reversible, drug-specific tolerance to stimulation of locomotor activity by caffeine.
Holtzman, SG, 1983
)
0.27
" No significant changes in dose-response curves were observed at either loci."( Effects of kainic acid lesions of the striatum on self-stimulation in the substantia nigra and ventral tegmental area.
Fibiger, HC; LePiane, FG; Phillips, AG, 1982
)
0.26
" Dose-response alteration of VI responding by apomorphine, d-amphetamine, clonidine, and chlordiazepoxide was studied along and in the presence of a dose of acrylamide which, by itself, did not alter VI responding."( The effects of acrylamide on the behavioral suppression produced by psychoactive agents.
Squibb, RE; Tilson, HA, 1982
)
0.26
" All strains responded similarly to d-amphetamine as is apparent from the parallel profiles for the dose-response curves."( The effect of varying doses of d-amphetamine on activity levels of prepubertal mice.
Cytryn, AS, 1980
)
0.26
" 1-(4-Hydroxy-3-methoxyphenyl)-2-(n-propylamino) propane was also recovered from the urine of rats dosed with the catecholamine (Id)."( In vivo and in vitro o-methylation of 1-(3,4-dihydroxyphenyl)-2-(n-propyl-amino) propane - an intermediate in N-(N-propyl) amphetamine metabolism.
Coutts, RT; Jones, GR, 1982
)
0.26
" Dose-response functions for dl-cathinone and d-amphetamine were then redetermined by substituting a test dose for the usual presession injection once every 4 to 5 days."( Behavioral tolerance and cross-tolerance to dl-cathinone and d-amphetamine in rats.
Foltin, RW; Schuster, CR, 1982
)
0.26
" These findings constitute biochemical evidence for selective elevation of brain DA during the first postnatal week of life after L-DOPA administration in a dosage that is also capable of enhancing the coordination required for swimming behavior."( Brain catecholamine concentration during the first week of development in rats.
Korányi, L; Phelps, CP; Tamásy, V, 1982
)
0.26
" Chronic but not acute administration of DMI potentiated the locomotor response to d-amphetamine within a narrow dosage range."( Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine.
Fibiger, HC; Spyraki, C, 1981
)
0.26
" Maximal response rates for NPA were about 1/2 of that of A, NMA and NEA, and the dose-response curve was shifted to the right of these compounds by about 4 times."( Structure-activity relationships among some d-N-alkylated amphetamines.
Johanson, CE; Shybut, G; Woolverton, WL, 1980
)
0.26
" Dose-response relationship of methylphenidate thermal effects exhibits a U-shape curve."( A comparison of the hypothermic effects of methylphenidate and d-amphetamine.
Ben-Uriah, Y; Carasso, RL; Yehuda, S, 1981
)
0.26
" All active compounds gave inverted U-shaped dose-response curves."( Cognition-activating properties of 3-(Aryloxy)pyridines.
Butler, DE; Marriott, JG; Poschel, BP, 1981
)
0.26
"Male and female rats of the Fischer Strain were dosed with 550 mg/kg of benzene or corn oil vehicle on Days 9, 11 and 13 postpartum."( Postnatal exposure to benzene alters the neurobehavioral functioning of rats when tested during adulthood.
Meyer, OA; Sparber, SB; Squibb, RE; Tilson, HA, 1980
)
0.26
" When graphically represented, the dose-response curves were shown to be parallel suggesting a common site and/or mechanism of action."( Effect of fenfluramine and nicotine upon a stimulant-depressant continuum.
Schechter, MD, 1981
)
0.26
" Administration of d-amphetamine sulfate produced similar dose-response functions for locomotor activity in both VMT-lesioned and sham-operated rats despite the extensive depletion of dopamine in the VMT-lesioned rats."( Effects of lesions of the ventral medial tegmentum on locomotor activity, biogenic amines and responses to amphetamine in rats.
Kant, GJ; Koob, GF; Meyerhoff, JL; Sessions, GR, 1980
)
0.26
" The combination of a clinically useful medication in appropriate dosage schedules with relevant psychological treatments simultaneously directed to each of the child's many disabilities were associated with an unexpectedly good outcome at the end of one and two years."( Multimodality treatment. A two-year evaluation of 61 hyperactive boys.
Cantwell, DP; Satterfield, BT; Satterfield, JH, 1980
)
0.26
"Cumulative dose-response curves have been widely used in many areas of pharmacology."( Cumulative dose-response curves in behavioral pharmacology.
Wenger, GR, 1980
)
0.26
"0 mg/kg) produced dose-dependent rightward shifts of the (+/-)BAY k 8644 dose-response curve."( Modification of the behavioral effects of (+/-)BAY k 8644, cocaine and d-amphetamine by L-type calcium channel blockers in squirrel monkeys.
Barrett, JE; Rosenzweig-Lipson, S, 1995
)
0.29
"5 mg/kg; Group A) or saline (Group S) at 3-day intervals developed sensitization of hypophagia, as assessed by a shift to the left in the dose-response (DR) function."( Development and reversal of sensitization to amphetamine-induced hypophagia: role of temporal, pharmacological, and behavioral variables.
Wolgin, DL, 1995
)
0.29
" Pretreatment also shifted to the right the dose-response function for DALA intra-accumbens."( Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.
Everitt, BJ; Phillips, GD; Robbins, TW, 1994
)
0.29
" In experiment 2b, a full d-amphetamine dose-response function was examined."( Isolation rearing impairs the reinforcing efficacy of intravenous cocaine or intra-accumbens d-amphetamine: impaired response to intra-accumbens D1 and D2/D3 dopamine receptor antagonists.
Everitt, BJ; Howes, SR; Phillips, GD; Robbins, TW; Whitelaw, RB, 1994
)
0.29
"25 mg/kg subcutaneously, at which dosage it is active only on supersensitive receptors of denervated neurons)."( Comparison between normal developing striatum and developing striatal grafts using drug-induced Fos expression and neuron-specific enolase immunohistochemistry.
Guerra, MJ; Labandeira-Garcia, JL; Tobio, JP, 1994
)
0.29
" Transient sedation lasting 2 to 3 days occurred after initial administration or dosage increase; otherwise, clonidine was well tolerated."( Clonidine therapy for comorbid attention deficit hyperactivity disorder and conduct disorder: preliminary findings in a children's inpatient unit.
Mandoki, MW; Schvehla, TJ; Sumner, GS, 1994
)
0.29
" Personal or family tic history, medication selection, or dosage was not related to onset of T/D."( Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder.
Adesman, AR; Goldstein, IJ; Lipkin, PH, 1994
)
0.29
" No dose-response relationship was found for either stimulant."( Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys.
Elia, J; Gullotta, CS; Rapoport, JL; Welsh, PA, 1993
)
0.52
" Therefore, a dose-response curve of posttraining injection (intraperitoneal) of fluoxetine was carried out in an associative learning task (auto-shaping)."( Effect of fluoxetine on learning and memory involves multiple 5-HT systems.
Hong, E; Meneses, A, 1995
)
0.29
" The latencies to first mount, intromission, and ejaculation were nonmonotonically related to dosage, being shortest at the lowest dosage in isolated mice, but significantly elevated by the higher dosages in both isolated and grouped males."( Differential sexual activity of isolated and group-housed male mice: influence of acute d-amphetamine sulfate administration.
deCatanzaro, D; Griffiths, J, 1996
)
0.29
" As animal studies and early clinical studies with ondansetron have suggested nonlinear dose-response relationships, three subjects also underwent pilot studies with three doses of ondansetron (0."( Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers.
Broocks, A; Canter, SK; Dubbert, B; Grady, TA; Hill, JL; Murphy, DL; Pigott, TA, 1996
)
0.29
"The time-lapse changes of d- and i-forms in urine specimens collected in the 24 h after the oral dosing of two adult male subjects with 20 mg of racemic (dl)-ethylamphetamine (EAMP)-HCl were examined by high-performance liquid chromatography."( Time-lapse changes of d- and l-enantiomers of racemic (dl)-ethylamphetamine in human urine.
Kamiyama, S; Kanaya, H; Matsushima, K; Nagai, T,
)
0.13
" Data obtained from a screening questionnaire, sleep diaries, and medical records showed that 22 of our 43 treated narcoleptic subjects reduced their dosage of stimulant medications or had not taken any stimulant medications during a 24-hour monitoring period during which they were expected to be on medication."( Compliance with stimulant medications in patients with narcolepsy.
Aldrich, MS; Berrios, AM; Rogers, AE; Rosenberg, RS, 1997
)
0.3
" Twenty-four men entered the study, 18 of 19 (95%) patients who completed at least 6 weeks of treatment reported substantial improvement with regard to both mood and energy at a median dosage of 10 mg/day."( Dextroamphetamine as a treatment for depression and low energy in AIDS patients: a pilot study.
Rabkin, JG; Rabkin, R; Wagner, GJ, 1997
)
1.74
" In experiment 1, a dexamphetamine dose-response curve (0."( No major differences in locomotor responses to dexamphetamine in high and low responders to novelty: a study in Wistar rats.
Cools, AR; Gingras, MA, 1997
)
0.3
" In Experiment 2, the dose-response function for this drug effect was examined."( Impact of d-amphetamine on temporal estimation in pigeons tested with a production procedure.
Brown, RW; Dose, JM; Kraemer, PJ; Randall, CK, 1997
)
0.3
" Furthermore, it was recently found that under a certain dosage and schedule, cocaine could produce a shift from a D1-characteristic to a D2-like EEG pattern."( Sensitization to d-amphetamine after its repeated administration: evidence in EEG and behaviour.
Ferger, B; Kuschinsky, K; Stahl, D, 1997
)
0.3
" A second experiment compared the evolution of changes in ETR, FL/HL-GS, and peripheral neurophysiological measures during 8 weeks of daily oral dosing of 10 mg/kg acrylamide (ACR) monomer."( Quantification of the hindlimb extensor thrust response in rats.
Carr, GJ; Fix, AS; Handley, DE; Lawhorn, GT; Ross, JF,
)
0.13
" On PND 8, unisexually reared females showed, upon maternal deprivation, a generalized shift to the left in the dose-response curve to AMPH for Crossing behaviour, while on PND 18 AMPH-induced stereotypies were considerably reduced in sexually segregated females, especially following maternal deprivation."( Sexual segregation in infant mice: behavioural and neuroendocrine responses to d-amphetamine administration.
Adriani, W; Cirulli, F; Laviola, G, 1997
)
0.3
" Rats were pretreated with vehicle or an agonist, then dose-response curves for d-amphetamine or cocaine were generated."( mu-, delta- and kappa-opioid receptor agonists do not alter the discriminative stimulus effects of cocaine or d-amphetamine in rats.
Holtzman, SG; Woolfolk, DR, 1997
)
0.3
" However, comparison of the dose-response curves for the drug and saline pre-exposed groups did not reveal evidence for sensitization to this d-amphetamine effect in drug-pre-exposed rats, despite indications that sensitization had developed to the locomotor stimulant effects of d-amphetamine."( Lack of sensitization to the effects of d-amphetamine and apomorphine on sensorimotor gating in rats.
Druhan, JP; Geyer, MA; Valentino, RJ, 1998
)
0.3
" In dose-response tests, subjects rarely responded on the U-50,488H-appropriate key when morphine was administered or on the morphine-appropriate key when they received U-50,488H."( Establishing morphine and U-50,488H as discriminative stimuli in a three-choice assay with pigeons.
Makhay, MM; Poling, A; Young, AM, 1998
)
0.3
" The present experiments extend these findings by investigating: (a) interactions between isolation rearing and repeated handling/testing on presynaptic DA function in the NAC using in vivo microdialysis: (b) the dose-response curve for the effects of d-amphetamine, and the responses elicited by high potassium, using in vivo microdialysis, and (c) postsynaptic function in isolates as indexed by DA receptor-linked cAMP production."( Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems.
Hall, FS; Humby, T; Inglis, W; Kendall, DA; Marsden, CA; Robbins, TW; Wilkinson, LS, 1998
)
0.3
" Results following bolus administration of these drugs were consistent with the cumulative dosing procedure, although of smaller magnitude and higher variability."( The effects of dopaminergic agents on reaction time in rhesus monkeys.
Gold, LH; Weed, MR, 1998
)
0.3
" Since psychostimulant treatment often requires frequent dosing and may be associated with unacceptable side effects and risks, other classes of medication have been studied as possible treatment alternatives."( Psychopharmacology of ADHD: children and adolescents.
Dogin, JW; Findling, RL, 1998
)
0.3
" A secondary goal was to determine the accuracy of Drug Recognition Examiners (DREs) in detecting if subjects were dosed with these drugs."( Laboratory validation study of drug evaluation and classification program: alprazolam, d-amphetamine, codeine, and marijuana.
Crouch, DJ; Heishman, SJ; Singleton, EG, 1998
)
0.3
" For example, the frequency and duration of 'moving' dose-dependently increased after cocaine, while d-amphetamine and caffeine again produced bell-shaped dose-response curves."( D-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioural patterns in rats.
Antoniou, K; Hyphantis, T; Kafetzopoulos, E; Marselos, M; Papadopoulou-Daifoti, Z, 1998
)
0.3
" Dose-response tests revealed that both drugged groups learned to suppress stereotypy in order to feed at 2 mg/kg, but only the non-sensitized group could do so at 4 mg/kg."( Experiential constraints on the development of tolerance to amphetamine hypophagia following sensitization of stereotypy: instrumental contingencies regulate the expression of sensitization.
Hughes, KM; Popi, L; Wolgin, DL, 1998
)
0.3
" Three groups of four rats each were used: control, d-amphetamine sulphate dosed (s."( Effect of d-amphetamine repeated administration on rat antioxidant defences.
Carvalho, F; de Lourdes Bastos, M; Fernandes, E; Remião, F, 1999
)
0.3
" Participants in the low-dose group exhibited a significant leftward shift in the dose-response function for discrimination performance, which is concordant with previous preclinical and human drug discrimination studies that assessed the effects of training dose."( Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans.
Kollins, SH; Rush, CR, 1999
)
0.3
" AMPH exerted a paradoxical effect on CORT secretion only in maternally deprived subjects while affecting behaviour mainly in deprived female subjects, which showed a generalised shift to the left in the dose-response curve to this drug."( Paradoxical effects of D-amphetamine in infant and adolescent mice: role of gender and environmental risk factors.
Cirulli, F; Laviola, G, 2000
)
0.31
" On the other hand, home-cage wheel-running activity was maximally inhibited by 10 mg/kg amphetamine, whereas a smaller dosage (1."( The effect of amphetamine on locomotion depends on the motor device utilized. The open field vs. the running wheel.
Della Maggiore, V; Ralph, MR, 2000
)
0.31
" These two dosing regimens were designed to evaluate sensitization as a shift in the dose-response relationship, inasmuch as a range of doses was imposed within each dosing session."( Dose-dependent effects but not sensitization of DRL 45-s performance by oral d-amphetamine with cumulative- and repeated-dosing regimens.
Falk, JL; Lobarinas, E, 1999
)
0.3
" Changing the unit dose produced a characteristic U-shaped dose-response curve."( RU-24969 disrupts d-amphetamine self-administration and responding for conditioned reward via stimulation of 5-HT1B receptors.
Fletcher, PJ; Korth, KM, 1999
)
0.3
"3 degrees C) but striatal tissue levels of dopamine 7 days after dosing were reduced only 25% or less by ephedrine compared to the 75% reductions produced by amphetamine."( An evaluation of l-ephedrine neurotoxicity with respect to hyperthermia and caudate/putamen microdialysate levels of ephedrine, dopamine, serotonin, and glutamate.
Bowyer, JF; Ferguson, SA; Gough, B; Newport, GD; Slikker, W; Tor-Agbidye, J, 2000
)
0.31
" Thirty-two reports (29 studies) evaluated adverse effects of drug therapy; many of the side effects associated with stimulant use appear to be relatively mild and of short duration and to respond to dosing or timing adjustments."( Treatment of attention-deficit/hyperactivity disorder.
Boyle, M; Cunningham, C; Jadad, AR; Kim, M; Schachar, R, 1999
)
0.3
"We examined the effects of Delta 9-tetrahydrocannabinol (Delta 9-THC), (R)-(+)-arachidonyl-1'-hydroxy-2'-propylamide ((R)-methanandamide, AM 356), SR 141716, and d-amphetamine on fixed-ratio (FR) responding maintained by food in rats before and during daily dosing with Delta 9-THC."( Effects of Delta 9-tetrahydrocannabinol, (R)-methanandamide, SR 141716,and d-amphetamine before and during daily Delta 9-tetrahydrocannabinol dosing.
Goutopoulos, A; Järbe, TU; Lamb, RJ; Lin, S; Makriyannis, A, 2000
)
0.31
" Results indicated that 3 children were able to accurately report their medication status at levels greater than chance, whereas the accuracy of reports by all children was related to dosage level, differences in behavior, and the presence of adverse effects."( Testing the ability of children with attention deficit hyperactivity disorder to accurately report the effects of medication on their behavior.
Ardoin, SP; Martens, BK, 2000
)
0.31
" Rats that did not become hyperthermic when dosed with 15 mg/kg AMPH in a cold environment (10 degrees C) exhibited some hyperactivity and stereotypic behavior, but not overt convulsive behavior."( Seizure activity and hyperthermia potentiate the increases in dopamine and serotonin extracellular levels in the amygdala during exposure to d-amphetamine.
Bowyer, JF; Tor-Agbidye, J; Yamamoto, B, 2001
)
0.31
" A treatment history of high AMPH dosage was associated with a marked sensitization of the exploratory behavior in adults, whereas it induced a quite opposite profile in periadolescents."( Striatal dopamine sensitization to D-amphetamine in periadolescent but not in adult rats.
Laviola, G; Pascucci, T; Pieretti, S, 2001
)
0.31
" Under the FR schedule, pentobarbital dose-response curves were usually quantal, whereas under the FI schedule the pentobarbital dose-response curves usually were graded."( Discrimination of pentobarbital doses and drug mixtures under fixed-ratio and fixed-interval reinforcement schedules.
Hardwick, WC; Li, M; McMillan, DE, 2001
)
0.31
" In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules."( Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial.
Creson, D; Daruzska, LA; Grabowski, J; Moeller, FG; Rhoades, H; Schmitz, J; Stotts, A, 2001
)
1.97
" Although parent behavior ratings and locomotor activity showed improvements up to 12 hours after single doses of all three drugs, the number of math problems attempted and completed correctly 4 hours after dosing were only robustly increased by Spansules."( Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD.
Bastain, TM; Castellanos, FX; Czarnolewski, M; James, RS; Lee, PP; Sharp, WS; Walter, JM, 2001
)
0.31
" Thus, drug discrimination can be established under concurrent VR VR schedules, but the shapes of drug-discrimination dose-response curves under concurrent VR VR schedules more closely resemble those seen under interval schedules than those seen under fixed-ratio schedules."( Drug discrimination under concurrent variable-ratio variable-ratio schedules.
Hardwick, WC; Li, M; McMillan, DE, 2002
)
0.31
" When dose-response curves were redetermined with a cumulative-dosing procedure, the same pattern of generalization occurred as under single-dose procedures."( Four-choice drug discrimination in pigeons.
Li, M; McMillan, DE, 2001
)
0.31
" The results indicate that administration of low-dose dextroamphetamine in this dosing regimen does not alter the steady-state pharmacokinetics of modafinil."( Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers.
Arora, S; Hellriegel, ET; Nelson, M; Robertson, P, 2002
)
0.78
" Measuring rectal body temperatures, dose-response relationships were established for all compounds."( Morphine and d-amphetamine nullify each others' hypothermic effects in mice.
Baker, A; Meert, T, 2003
)
0.32
" After responding stabilized, dose-response curves were determined for other drugs."( Retention of sequential drug discriminations under fixed-interval schedules for long time periods without training.
Li, M; McMillan, DE, 2003
)
0.32
"In a controlled study (the control group receiving pyribenzamine) it was observed that reserpine, in the dosage used, had no effect on weight loss in patients receiving d-amphetamine sulphate (Dexedrine(R)) and methyl cellulose (Cellothyl(R)) while on 1,000-calorie diets as compared with the control group."( Reserpine in weight reduction. The effect in obese patients on 1,000-calorie diets: a controlled study.
SMITH, MC, 1959
)
0.24
" The pressor responses to tyramine and to phenethylamine declined slowly with repeated injection; the extent of tachyphylaxis induced by these amines depended on the dosage and on the frequency of injection."( TACHYPHYLAXIS TO SOME SYMPATHOMIMETIC AMINES IN RELATION TO MONOAMINE OXIDASE.
DAY, MD; RAND, MJ, 1963
)
0.24
" In the present patient population, a predetermined AUC value can be obtained by a dosing regimen of dexamphetamine based on body weight (ie, mg/kg), with precautions for patients with elevated s-creatinine."( Pharmacokinetics of dexamphetamine in acute stroke.
Beck, O; Eksborg, S; Martinsson, L; Wahlgren, NG; Yang, X,
)
0.13
" Dose-response curves were generated to examine the effect of three doses of baclofen (1."( Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates.
Ahn, S; Brebner, K; Phillips, AG, 2005
)
0.33
" In dose-response experiments, we tested successive 10-day intervals of exposure to MA in rats (P21-30, P31-40, P41-50, and P51-60; four doses per day)."( Periadolescent rats (P41-50) exhibit increased susceptibility to D-methamphetamine-induced long-term spatial and sequential learning deficits compared to juvenile (P21-30 or P31-40) or adult rats (P51-60).
Brown, CA; Fukumura, M; McCrea, AE; Morford, LL; Reed, TM; Rock, SL; Skelton, MR; Vorhees, CV; Williams, MT; Wood, SL,
)
0.13
"001), which corresponded to a leftward shift in the dose-response curve."( Association between the casein kinase 1 epsilon gene region and subjective response to D-amphetamine.
Cook, EH; de Wit, H; Palmer, AA; Qaadir, A; Veenstra-VanderWeele, J, 2006
)
0.33
" Increased intensity and longer duration drug/therapy dosing regimens should be explored, targeting the upper and lower limbs separately."( Physiotherapy coupled with dextroamphetamine for rehabilitation after hemiparetic stroke: a randomized, double-blind, placebo-controlled trial.
Armesto, A; Black, SE; Danells, CJ; Gladstone, DJ; Graham, SJ; Herrmann, N; McIlroy, WE; Staines, WR; Szalai, JP, 2006
)
0.63
" Therefore, experiments were carried out in P-gp knockout (KO) mice versus wild-type (WT) mice after intraperitoneal dosing (2."( The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine.
DeVane, CL; Donovan, JL; Gibson, BB; Markowitz, JS; Middaugh, LD; Patrick, KS; Wang, JS; Williard, RL; Zhu, HJ, 2006
)
0.33
"1 mg/kg/injection) functioned as a positive reinforcer with sigmoidal or biphasic dose-response functions."( Self-administration of mixtures of fenfluramine and amphetamine by rhesus monkeys.
Wee, S; Woolverton, WL, 2006
)
0.33
"0 mg/kg d-amphetamine sulfate, and this dosing regimen induced head movements with a rhythm near 10 Hz."( Clozapine and prazosin slow the rhythm of head movements during focused stereotypy induced by d-amphetamine in rats.
Fowler, SC; Pinkston, JW; Vorontsova, E, 2007
)
0.34
"5 mg/kg amphetamine and to a cumulative dosing of amphetamine."( Social defeat stress, sensitization, and intravenous cocaine self-administration in mice.
Miczek, KA; Yap, JJ, 2007
)
0.34
" In a 7-day repeat-dose study, all rats dosed with LDX (14 per dose group for each sex) showed increased activity; 10 male rats and 11 female rats at 300 mg/kg/day and 3 female rats at 100 mg/kg/day were euthanized because of self-mutilation and 1 male rat at 300 mg/kg/day was found dead."( Toxicity profile of lisdexamfetamine dimesylate in three independent rat toxicology studies.
Krishnan, S; Montcrief, S, 2007
)
0.34
" Because his supply of amphetamine-dextroamphetamine was diminishing, he took only half (30 mg every morning) of his prescribed dosage from days 4-12 of varenicline therapy."( Interference with smoking-cessation effects of varenicline after administration of immediate-release amphetamine-dextroamphetamine.
Moorman, KL; Whitley, HP, 2007
)
0.83
" Similar findings were seen after treatment with d-amphetamine up to the dosage where focused stereotypies dominated behavioral response."( A novel method for automatic quantification of psychostimulant-evoked route-tracing stereotypy: application to Mus musculus.
Bonasera, SJ; Luxenberg, EJ; Schenk, AK; Tecott, LH, 2008
)
0.35
" However, several limitations to the study, including the small sample size, low dosage of D-amphetamine, and the fact that D-amphetamine increases synaptic concentrations of DA and other monoamine neurotransmitters do not permit a conclusion regarding a specific role for DA in the observed increase in spatial activation to blue light in the amphetamine condition."( Differential effects of D-amphetamine on red and blue light-induced photic activation: A novel BOLD fMRI assay of human dopamine function.
Cowan, RL; de B Frederick, B; Dietrich, MS; Lukas, SE; Renshaw, PF; Wood, J, 2008
)
0.35
" The medications are sometimes dispensed as custom dosage forms in gelatin capsules for convenience."( Relative bioavailability of scopolamine dosage forms and interaction with dextroamphetamine.
Boyd, JL; Du, B; Locke, JP; Putcha, L; Vaksman, Z, 2007
)
0.57
" Dosing regimens were based on reported or concurrently determined wake-promoting activities in canine models."( Hemodynamic and cardiac neurotransmitter-releasing effects in conscious dogs of attention- and wake-promoting agents: a comparison of d-amphetamine, atomoxetine, modafinil, and a novel quinazolinone H3 inverse agonist.
Bone, A; Fujino, N; Gilberto, D; Johnson, C; Lynch, J; Nagase, T; Regan, C; Renger, J; Sato, N; Stevens, J; Stump, G; Takenaga, N; Tannenbaum, P; Tokita, S, 2009
)
0.35
" The unique pharmacokinetic profile owing to lisdexamfetamine's prodrug design and rate-limited enzymatic biotransformation allows for once-daily dosing with a duration of activity of approximately 12 hours."( Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.
Cowles, BJ, 2009
)
0.35
" Continued METH dosing in the surviving groups did not affect the mean pups/litter weight at the end of the experiment on GD21."( Vulnerability to (+)-methamphetamine effects and the relationship to drug disposition in pregnant rats during chronic infusion.
Gentry, WB; Hendrickson, HP; Laurenzana, EM; Owens, SM; Ward, KW; White, SJ; Williams, DK, 2009
)
0.35
" Following oral dosing of antipsychotics, peaks and troughs in plasma drug concentrations may be mirrored by fluctuations in D(2)-receptor occupancy."( A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats.
Casu, G; Deriu, A; Lazzari, P; Marchese, G; Pani, L; Peddio, G; Pira, M; Pisu, C; Pittau, B; Portesani, F; Spada, GP, 2010
)
0.36
" Experiment 2: rats were trained to self-administer cocaine under a PR schedule and initial dose-response curves were determined before implantation of D-amphetamine mini-pumps."( Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats.
Chiodo, KA; Roberts, DC, 2009
)
0.35
" Children whose aggressive behavior persisted at the conclusion of the lead-in phase were randomly assigned to receive double-blind, flexibly dosed divalproex or a placebo adjunctive to stimulant for 8 weeks."( Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy.
Blader, JC; Jensen, PS; Kafantaris, V; Pliszka, SR; Schooler, NR, 2009
)
0.35
" The recommended starting dosage of lisdexamfetamine is 30 mg orally daily, which can be adjusted to a maximum dosage of 70 mg daily."( Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder.
Bhattacharya, P; Popovic, B; Sivaswamy, L, 2009
)
0.35
" During Phase 1, two groups of pigeons experienced one of these procedures while being administered with D-amphetamine in an ABA chronic dosing regimen."( ABA chronic dosing of D-amphetamine produces differential drug effects in two variants of a temporal discrimination procedure in pigeons.
McClure, EA; Saulsgiver, KA; Wynne, CD, 2009
)
0.35
" Rats received an escalating (1-8 mg/kg) dosing regimen of D-AMPH for five weeks and were euthanized 28 days later."( A sensitizing D-amphetamine dose regimen induces long-lasting spinophilin and VGLUT1 protein upregulation in the rat diencephalon.
Boikess, SR; Marshall, JF; O'Dell, SJ, 2010
)
0.36
" Dexmethylphenidate XR is a stimulant treatment in a single isomer form, and has an efficacy and tolerability similar to two doses of immediate-release (IR) dexmethylphenidate when taken 4 hours apart, but is dosed at half of the usual d,l-methylphenidate dose."( Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
Kratochvil, CJ; May, DE, 2010
)
0.36
" Two models are proposed to analyze the dose-response time-to-event data that typically result from such experiments: (1) a linear regression model and (2) an E(max) model with latent drug concentration at the site of action."( A latent pharmacokinetic time profile to model dose-response survival data.
Adriaan Bouwknecht, J; Bijnens, L; Jacobs, T; Molenberghs, G; Straetemans, R, 2010
)
0.36
" d-Amphetamine produced prototypical stimulant effects (eg, increased subject ratings of Stimulated and Like Drug, elevated heart rate and blood pressure, and improved rate and accuracy on the digit symbol substitution task) irrespective of dose, but the onset of these effects was generally earlier following intranasal administration, with significant effects emerging 15 to 30 minutes after intranasal dosing and 45 to 60 minutes after oral dosing."( Comparison of the behavioral and cardiovascular effects of intranasal and oral d-amphetamine in healthy human subjects.
Babalonis, S; Emurian, C; Kelly, TH; Lile, JA; Martin, CA; Wermeling, DP, 2011
)
0.37
" After determining a dose-response curve for cocaine (0."( Prolonged attenuation of the reinforcing strength of cocaine by chronic d-amphetamine in rhesus monkeys.
Czoty, PW; Gould, RW; Martelle, JL; Nader, MA, 2011
)
0.37
" Possible reasons for difference from mideastern reports include endemic diets, population genetics, relative rate of zinc deficiency, difference in background nutrition, insufficient dosage or absorption, or wrong anion (sulfate may be necessary for reported benefit)."( Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine.
Abdel-Rasoul, M; Arnold, LE; Bozzolo, D; Bozzolo, H; Crowl, L; Disilvestro, RA; Fernandez, S; Joseph, E; Mo, X; Ramadan, Y; Thompson, S, 2011
)
0.37
"To explore dose-response effects of lisdexamfetamine dimesylate (LDX) treatment for ADHD."( Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study.
Faraone, SV; Glatt, SJ; Goodman, D; Kollins, SH; Spencer, TJ, 2012
)
0.38
"For LDX doses between 30 and 70 mg/d, the dose-response efficacy effect for LDX is not affected by prior pharmacotherapy, but patients with a greater severity of illness may benefit more from higher doses, especially for hyperactive-impulsive symptoms."( Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study.
Faraone, SV; Glatt, SJ; Goodman, D; Kollins, SH; Spencer, TJ, 2012
)
0.38
" Following a 2-day drug-free period, dose-response curves for hyperactivity produced by MDMA (2."( Repeated exposure to MDMA and amphetamine: sensitization, cross-sensitization, and response to dopamine D₁- and D₂-like agonists.
Bradbury, S; Gittings, D; Schenk, S, 2012
)
0.38
" In the present studies, dose-response curves for d-amphetamine (AMPH)-induced hyperlocomotion were similar in standard B6 mice and in the BTBR mouse model of autism."( Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism.
Babineau, BA; Crawley, JN; Karras, MN; Oliver, CF; Silverman, JL, 2013
)
0.39
" However, later timing of stimulant dosing was correlated with later sleep times, p < ."( Adults with ADHD-without insomnia history have subclinical sleep disturbance but not circadian delay: an ADHD phenotype?
Fargason, RE; Gamble, KL; Hollar, AF; White, S, 2013
)
0.39
") dose-response curves were determined, self-administration sessions were suspended and MPD (0."( Effects of chronic methylphenidate on cocaine self-administration under a progressive-ratio schedule of reinforcement in rhesus monkeys.
Czoty, PW; Gould, RW; Martelle, SE; Nader, MA, 2013
)
0.39
" To evaluate the efficacy of LDX throughout the day, symptoms and behaviors of ADHD were evaluated using an abbreviated version of the Conners' Parent Rating Scale-Revised (CPRS-R) at 1000, 1400 and 1800 hours following early morning dosing (0700 hours)."( Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial.
Banaschewski, T; Bloomfield, R; Civil, R; Coghill, DR; Dittmann, RW; Lecendreux, M; Otero, IH; Squires, LA; Zuddas, A, 2014
)
0.4
" Additionally, a dose-response relationship was observed, such that the strength of these associations increased with higher doses of amphetamine."( Inattention, impulsive action, and subjective response to D-amphetamine.
de Wit, H; Weafer, J, 2013
)
0.39
"To compare therapy augmentation and deviation rates from the recommended once-daily dosing regimen in Attention Deficit Hyperactivity Disorder (ADHD) patients initiated on lisdexamfetamine (LDX) vs other once-daily Food and Drug Administration (FDA) approved stimulants."( Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Cloutier, M; Erder, MH; Gauthier, G; Guérin, A; Hodgkins, P; Setyawan, J; Wu, E, 2013
)
0.39
" Therapy augmentation and deviation rates from the recommended once-daily dosing regimen were compared between treatment groups using multivariate logistic regression models."( Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Cloutier, M; Erder, MH; Gauthier, G; Guérin, A; Hodgkins, P; Setyawan, J; Wu, E, 2013
)
0.39
"Overall, compared to LDX-treated patients, patients initiated on other ADHD medications were equally or more likely to have a therapy augmentation and more likely to deviate from the recommended once-daily dosing regimen."( Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
Cloutier, M; Erder, MH; Gauthier, G; Guérin, A; Hodgkins, P; Setyawan, J; Wu, E, 2013
)
0.39
"Because of very few side-effects and no drug dependence in the dosage used, sympathomimetic amines should be considered for first-line therapy."( Sympathomimetic amines effectively control pain for interstitial cystitis that had not responded to other therapies.
Check, JH; Cohen, G; Cohen, R; Dipietro, J; Steinberg, B, 2013
)
0.39
"Two hours after her first dosage of the sympathomimetic amine, she had a bowel movement and has had regular bowel movements ever since."( The use of sympathomimetic amines for the treatment of severe constipation refractory to conventional therapy--case report.
Check, JH; Katsoff, B, 2013
)
0.39
" All subjects were initiated at 30 mg/day of adjunctive LDX for the first week with flexible dosing (i."( The effect of lisdexamfetamine dimesylate on body weight, metabolic parameters, and attention deficit hyperactivity disorder symptomatology in adults with bipolar I/II disorder.
Almagor, D; Alsuwaidan, M; Bilkey, TS; Cha, DS; Gallaugher, LA; Kennedy, SH; McIntyre, RS; Powell, AM; Soczynska, JK; Szpindel, I; Woldeyohannes, HO, 2013
)
0.39
"The present results support the continued evaluation of an opioid receptor antagonist combined with a GABAA-positive modulator using more clinically relevant experimental conditions like examining the effect of chronic dosing with these drugs on methamphetamine self-administration."( Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.
Lile, JA; Marks, KR; Rush, CR; Stoops, WW, 2014
)
0.4
"5, 5 or 10mg/kg for its physical dependence potential in a repeated dose non-precipitated withdrawal test, for its drug profiling in a drug discrimination learning procedure (single escalating doses), and for its reinforcing properties in a conditioned place preference test (alternate dosing days) and an intravenous self-administration procedure (0."( Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
Geuens, SM; Geys, HM; Meert, TF; Stinissen, P; Teuns, GB,
)
0.13
"Cessation of subchronic dosing up to 10mg/kg methylphenidate led to sustained or even exacerbated effects on locomotion and behavior, body temperature, body weight, food consumption, and alteration of the diurnal rhythm during withdrawal."( Abuse liability assessment in preclinical drug development: predictivity of a translational approach for abuse liability testing using methylphenidate in four standardized preclinical study models.
Geuens, SM; Geys, HM; Meert, TF; Stinissen, P; Teuns, GB,
)
0.13
" Here we describe the effects of a sensitising dosage pattern of dextroamphetamine on the neural correlates of motor sequence learning in healthy volunteers, within a randomised, double-blind, parallel-groups design."( Amphetamine sensitisation and memory in healthy human volunteers: a functional magnetic resonance imaging study.
Joyce, D; Murray, RM; O'Daly, OG; Shergill, S; Stephan, KE; Tracy, DK, 2014
)
0.64
" Here we describe the effects of acute amphetamine administration, following a sensitising dosage regime, on blood oxygen level dependent (BOLD) signal in dopaminoceptive brain regions during a rewarded gambling task performed by healthy volunteers."( Amphetamine sensitization alters reward processing in the human striatum and amygdala.
Azim, A; Joyce, D; Murray, RM; O'Daly, OG; Shergill, SS; Stephan, KE; Tracy, DK, 2014
)
0.4
" By study phase, Eight of 27 (30%) patients remitted with initial dosing of tranylcypromine up to 60 mg/d, 6/18 (33%) remitted with above PDR dosing of tranylcypromine up to 120 mg/d, and 1/6 (17%) to adding dextroamphetamine."( How treatable is refractory depression?
Deliyannides, DA; McGrath, PJ; Stewart, JW, 2014
)
0.59
" Dose-response gradients were then obtained under 22-h and 46-h deprivation levels."( Increasing food deprivation relative to baseline influences D-amphetamine dose-response gradients.
Edwards, TL; Lotfizadeh, AD; Poling, A; Watkins, EE; Zimmermann, ZJ, 2014
)
0.4
" The dosage of lisdexamfetamine was 30 to 70 mg/day."( Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.
Maneeton, B; Maneeton, N; Martin, SD; Reungyos, J; Srisurapanont, M; Suttajit, S, 2014
)
0.4
" The dosage could be increased to 60 mg depending on tolerance to the medication and degree of improvement of the condition."( Sympathomimetic amines are a safe, highly effective therapy for several female chronic disorders that do not respond well to conventional therapy.
Check, JH, 2015
)
0.42
" This suggests that researchers should fully explore dose-response relationships in their strain of choice and use care in the interpretation of reversal of cognitive impairment."( Cross-site strain comparison of pharmacological deficits in the touchscreen visual discrimination test.
Chapin, D; Ding, Z; Kozak, R; Mohler, EG; Rueter, LE; Young, D, 2015
)
0.42
"For psychostimulants, a marked individual variability in the dose-response relationship and large differences in plasma concentrations after similar doses are known."( Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection.
Dörfelt, A; Haen, E; Stegmann, B, 2016
)
0.43
" We considered two independent studies that used different dosing regimens where subjects completed the drug effects questionnaire at multiple time points post d-amphetamine."( Individual differences in timing of peak positive subjective responses to d-amphetamine: Relationship to pharmacokinetics and physiology.
Cowan, RL; de Wit, H; Kessler, RM; Palmer, AA; Smith, CT; Weafer, J; Zald, DH, 2016
)
0.43
" Our LDX dosing regimen yielded blood levels of dextroamphetamine comparable to those documented in patients."( Longitudinal magnetic resonance imaging reveals striatal hypertrophy in a rat model of long-term stimulant treatment.
Bansal, R; Biezonski, D; Cha, J; Duan, Y; Gerum, S; Guilfoyle, DN; Hrabe, J; Kellendonk, C; Krivko, A; Leventhal, BL; Peterson, BS; Posner, J; Shah, R; Xie, S, 2016
)
0.69
" were less impulsive) with a higher rate of nose poking during the delay, and exhibited a compressed dose-response function (i."( 'Waiting impulsivity' in isolation-reared and socially-reared rats: effects of amphetamine.
Liu, YP; Robbins, TW; Wilkinson, LS, 2017
)
0.46
" Dose-response curves were then generated with AMPH (0."( Effects of D1 and D2 receptor antagonists on the discriminative stimulus effects of methylendioxypyrovalerone and mephedrone in male Sprague-Dawley rats trained to discriminate D-amphetamine.
Baker, LE; Burroughs, RL; Harvey, EL, 2017
)
0.46
" In one study, tics limited further dosage increases of methylphenidate."( Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland, ST; Pringsheim, T; Steeves, TD, 2018
)
0.48
" To evaluate the effects of GPR139 pharmacological activation on sleep, rats were orally dosed with the selective GPR139 agonist JNJ-63533054 (3-30 mg/kg)."( Putative role of GPR139 on sleep modulation using pharmacological and genetic rodent models.
Bonaventure, P; Dugovic, C; Dvorak, C; Liu, C; Lord, B; Lovenberg, T; Wang, L; White, A; Yun, S, 2020
)
0.56
" dosing and dispensation protocols) can be adjusted to allow for various scenarios (e."( Exploring the effectiveness of dextroamphetamine for the treatment of stimulant use disorder: a qualitative study with patients receiving injectable opioid agonist treatment.
Bojanczyk-Shibata, A; Harrison, S; Jun, J; Lock, K; MacDonald, S; Marchand, K; Marsh, DC; Oviedo-Joekes, E; Palis, H; Peachey, GS; Schechter, MT; Westfall, J, 2021
)
0.91
" To this aim, we conducted a dose-response study in male rats and assessed AMPH-induced hyperactivity and 50-kHz ultrasonic calling in the sender and social approach behavior evoked by playback of pro-social 50-kHz USV in the receiver."( Acute anxiogenic effects of escitalopram are associated with mild alterations in D-amphetamine-induced behavior and social approach evoked by playback of 50-kHz ultrasonic vocalizations in rats.
Schwarting, RKW; Willadsen, M; Wöhr, M, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
neurotoxinA poison that interferes with the functions of the nervous system.
adrenergic uptake inhibitorAdrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
dopaminergic agentA drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.
sympathomimetic agentA drug that mimics the effects of stimulating postganglionic adrenergic sympathetic nerves. Included in this class are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.
dopamine uptake inhibitorA dopaminergic agent that blocks the transport of dopamine into axon terminals or into storage vesicles within terminals. Most of the adrenergic uptake inhibitors also inhibit dopamine uptake.
adrenergic agentAny agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
1-phenylpropan-2-amineA primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.00230.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Phenylethanolamine N-methyltransferaseBos taurus (cattle)Ki435.33330.00312.329310.0000AID145544; AID156054
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Ki370.00000.00081.09276.0000AID125208; AID125210
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki14.40000.00192.379710.0000AID459599
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)0.63100.00081.541620.0000AID752492
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki0.10100.00031.465610.0000AID752492
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki280.00000.00061.777110.0000AID459600
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)16.59590.00010.86458.7096AID752491
Sodium-dependent serotonin transporterHomo sapiens (human)Ki5.72800.00000.70488.1930AID752491
Amine oxidase [flavin-containing] BBos taurus (cattle)Ki300.00000.05401.83906.0000AID125205
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)0.28840.00071.841946.0000AID752493
Sodium-dependent dopamine transporter Homo sapiens (human)Ki0.10900.00021.11158.0280AID752493
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Kd4.46680.00042.58328.5114AID6406
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Kd4.46680.00012.62198.5114AID6406
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Kd4.46680.00012.29338.5114AID6406
Sodium-dependent noradrenaline transporter Homo sapiens (human)EC50 (µMol)0.21000.082031.0243168.9080AID635292
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)EC50 (µMol)0.02500.00070.17911.4500AID1442370
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Kd4.46680.00042.47358.5114AID6406
5-hydroxytryptamine receptor 6Rattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
Sodium-dependent serotonin transporterHomo sapiens (human)EC50 (µMol)0.14000.00112.38838.7000AID635296
Sodium-dependent serotonin transporterRattus norvegicus (Norway rat)EC50 (µMol)1.76500.00070.42361.7650AID1442369
5-hydroxytryptamine receptor 7 Rattus norvegicus (Norway rat)Kd4.46680.00012.70068.5114AID6406
5-hydroxytryptamine receptor 5ARattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
5-hydroxytryptamine receptor 5BRattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
5-hydroxytryptamine receptor 3ARattus norvegicus (Norway rat)Kd4.46680.00082.62148.5114AID6406
Sodium-dependent dopamine transporter Homo sapiens (human)EC50 (µMol)0.99000.01250.76681.7000AID635295
5-hydroxytryptamine receptor 4 Rattus norvegicus (Norway rat)Kd4.46680.02342.74218.5114AID6406
Trace amine-associated receptor 1Macaca mulatta (Rhesus monkey)EC50 (µMol)1.01001.01002.57755.3000AID635287
Trace amine-associated receptor 1Mus musculus (house mouse)EC50 (µMol)0.10390.00200.69705.4000AID1066366; AID1066368; AID1066370; AID635292; AID635293
Trace amine-associated receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.53280.01390.42632.0440AID1066367; AID1066369; AID1066371; AID635289; AID635290; AID635291
Trace amine-associated receptor 1Homo sapiens (human)EC50 (µMol)0.66630.01501.41437.1900AID341210; AID635286; AID635295; AID635296
5-hydroxytryptamine receptor 3BRattus norvegicus (Norway rat)Kd4.46680.00082.62148.5114AID6406
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.99000.10601.07651.7000AID635295
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (69)

Processvia Protein(s)Taxonomy
methylationPhenylethanolamine N-methyltransferaseBos taurus (cattle)
epinephrine biosynthetic processPhenylethanolamine N-methyltransferaseBos taurus (cattle)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
G protein-coupled receptor signaling pathwayTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (36)

Processvia Protein(s)Taxonomy
phenylethanolamine N-methyltransferase activityPhenylethanolamine N-methyltransferaseBos taurus (cattle)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
monoamine oxidase activityAmine oxidase [flavin-containing] BBos taurus (cattle)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
G protein-coupled receptor activityTrace amine-associated receptor 1Homo sapiens (human)
trace-amine receptor activityTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BBos taurus (cattle)
mitochondrial outer membraneAmine oxidase [flavin-containing] BBos taurus (cattle)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneTrace amine-associated receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (110)

Assay IDTitleYearJournalArticle
AID118784Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 0.32 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1442388Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate MDMA assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID178743Effective dose was evaluated for drug discrimination in I-trained rats1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA).
AID359909Inhibition of dopamine transporter-mediated [3H]dopamine uptake in Wistar rat striatal synaptosomes by liquid scintillation spectrometry1995Journal of natural products, Oct, Volume: 58, Issue:10
Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes.
AID118798Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 2.5 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID118796Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 1.25 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID1476941Substrate activity at human DAT expressed in HEK293 cells assessed as induction of DAT-mediated [3H]MPP+ release at 10 uM measured every 2 mins by liquid scintillation counting2017Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22
Heterocyclic Analogues of Modafinil as Novel, Atypical Dopamine Transporter Inhibitors.
AID1066369Activation of rat TAAR1 transmembrane domain 6 Met268(6.55)Thr mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID635287Activation of rhesus monkey TAAR1 expressed in RD-HGA16 cells co-expressing Gq protein assessed as cAMP accumulation by fluorescence plate reader2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1132107Toxicity in rat assessed as lymphopenia1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Linked Aryl Aryloxypropanolamines as a new class of lipid catabolis agents.
AID635297Inhibition of [3H]norepinephrine reuptake at human NET cloned in rat brain synaptosome by scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1442398Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate S(+)AMPH assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1066370Activation of mouse wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID359910Ratio of IC50 for rat striatum dopamine D1 receptor to IC50 for Wistar rat striatal synaptosomes dopamine transporter-mediated [3H]dopamine uptake1995Journal of natural products, Oct, Volume: 58, Issue:10
Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1066362Activation of mouse TAAR1 transmembrane domain 6 Thr268(6.55)Met mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID459596Selectivity ratio of Ki for rat MAOA to Ki for rat MAOB2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
AID1066360Activation of mouse TAAR1 transmembrane domain 7 Tyr287(7.39)Asn mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID111826Ability to reverse electroconvulsive shock induced amnesia in mice, after administering intraperitoneally at a dose of 1.25 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID459597Inhibition of MAOA in rat brain mitochondrial suspension2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
AID111832Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 2.5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1066368Activation of mouse TAAR1 transmembrane domain 6 Thr268(6.55)Met mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1442374Induction of stimulus generalization in rat trained to discriminate S(+)methamphetamine assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID635296Activation of human TAAR1 expressed in human HEK293T cells assessed as cAMP accumulation after 10 mins by BRET assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID118785Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 0.63 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID781325pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 20092014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID111842Compound was evaluated for the ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 5 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID112622Compound was tested for antidepressant activity against reserpine induced ptosis in mice after intraperitoneal administration; NT is not tested.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID635289Activation of rat TAAR1 expressed in HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by liquid scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID635295Activation of human TAAR1 expressed in Syrian hamster AV12-664 cells co-expressing GalphaS protein assessed as accumulation of cAMP after 30 mins using cAMP XS EA/CL as substrate by luminescence method in presence of RX821002 and alprenolol2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1442390Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate alpha-ET assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1066371Activation of rat wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1066363Activation of rat TAAR1 transmembrane domain 6 Met268(6.55)Thr mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID156054In vitro binding affinity of compound towards bovine adrenal phenylethanolamine N-methyl-transferase (PNMT)1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Stereochemical aspects of phenylethanolamine analogues as substrates of phenylethanolamine N-methyltransferase.
AID178390Effective dose for drug discrimination assay in rats using (+)-amphetamine as training drug1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA).
AID752493Inhibition of [3H]dopamine uptake at human DAT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID1442399Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate S(-)MCAT assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID635300Binding affinity to rat alpha adrenergic receptor2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID169888Number of rats falling (4) within each stereotypy classification after intraperitoneal administration (27 uM/Kg); continuous sniffing, with repetitive sequences of head and limb movements, as well as some licking and rearing (total
rats 4)
1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene.
AID1442369Activity at SERT in rat synaptosomes assessed as release of [3H]HT after 5 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID192059Compound was evaluated for the dose required to increase spontaneous motor activity (SMA) to 200% was reported1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene.
AID1066367Activation of rat TAAR1 transmembrane domain 7 Asn287(7.39)Tyr mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID635299Inhibition of [3H]5-HT uptake at human SERT cloned in rat brain synaptosome by scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID635298Inhibition of [3H]dopamine reuptake at human DAT cloned in rat brain synaptosome by scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1066359Selectivity ratio of EC50 for mouse wild type TAAR1 to EC50 for mouse TAAR1 transmembrane domain 6 Thr268(6.55)Met mutant2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID118797Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 10 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID635292Activation of mouse TAAR1 expressed in human HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by liquid scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID114239Serotonergic activity by measuring the potentiation of 5-hydroxy tryptophan in mice upon ip administration; NT is not tested.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID635294Activation of chimeric rat-human expressed in human HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by liquid scintillation counting2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID125210Competitive inhibition of Rat liver Monoamine Oxidase B at 37 degree C (pH= 7.4)1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site.
AID1066364Activation of mouse wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID1442382Displacement of [3H]DTG from sigma receptor (unknown origin)2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID111825Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.63 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID145543Inhibitory activity against Norepinephrine N-methyl-transferase of bovine adrenal glands1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Importance of the aromatic ring in adrenergic amines. 7. Comparison of the stereoselectivity of norepinephrine N-methyltransferase for aromatic vs. nonaromatic substrates and inhibitors.
AID1132072Antiobesity activity in mouse assessed as reduction in utero fat at 0.04% administered every day through diet for 10 days measured after day 10 relative to control1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Linked Aryl Aryloxypropanolamines as a new class of lipid catabolis agents.
AID125208Competitive inhibition of Rat liver Monoamine Oxidase B at 30 degree C (pH= 7.2)1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site.
AID1442400Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate rac-cathinone assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID459595Selectivity ratio of Ki for human MAOA to Ki for human MAOB2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
AID115598Ability to modify turning behavior of rats after intraperitoneal administration.1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
3-aminopyridazine derivatives with atypical antidepressant, serotonergic, and dopaminergic activities.
AID145544Inhibitory activity against bovine adrenal norepinephrine N-methyl-transferase was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Probes of the active site of norepinephrine N-methyltransferase: effect of hydrophobic and hydrophilic interactions on side-chain binding of amphetamine and alpha-methylbenzylamine.
AID175691Effective concentration was measured for the release of accumulated [3H]dopamine from chopped striatum of rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Pronounced pharmacological differences arising from minor structural changes in conformationally defined amphetamine analogues. Comparative evaluation of endo- and exo-2-amino- and endo- and exo-2-(methylamino)benzobicyclo[2.2.1]heptene and -benzobicylco[
AID1442387Induction of stimulus generalization in Sprague-Dawley rat trained to discriminate AMPH assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID752492Inhibition of [3H]norepinephrine uptake at human NET expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID125205Inhibitory activity against Monoamine Oxidase B of Bovine liver in competitive inhibition assay at 25 degree C (pH=7.4)1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site.
AID459599Inhibition of human recombinant MAOA by spectrophotometrically2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
AID1066373Activation of rat TAAR1 Asp102(3.32)Ala mutant expressed in HEK293 cells assessed as stimulation of cAMP production at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to control2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID353103Displacement of [3H]MK801 from NMDA receptor in rat brain neuronal membrane2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds.
AID341211Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay relative to 2-phenylethanamine2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID635286Activation of C-terminal HA epitope tagged human TAAR1 expressed in RD-HGA16 cells co-expressing Gq protein, Galpha16 by cAMP accumulation assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID180307Inhibitory concentration against uptake of [3H]NE into chopped cerebral cortical tissue from rat brain1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Pronounced pharmacological differences arising from minor structural changes in conformationally defined amphetamine analogues. Comparative evaluation of endo- and exo-2-amino- and endo- and exo-2-(methylamino)benzobicyclo[2.2.1]heptene and -benzobicylco[
AID1132073Antiobesity activity in mouse assessed as reduction in utero fat at 0.01% administered every day through diet for 10 days measured after day 10 relative to control1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Linked Aryl Aryloxypropanolamines as a new class of lipid catabolis agents.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1066366Activation of mouse TAAR1 transmembrane domain 7 Tyr287(7.39)Asn mutant expressed in HEK293 cells assessed as stimulation of cAMP production after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID635291Activation of rat TAAR1 expressed in Syrian hamster AV12-664 cells assessed as accumulation of cAMP after 30 mins using cAMP XS EA/CL as substrate by luminescence method2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID752491Inhibition of [3H]5-HT uptake at human SERT expressed in HEK293 cells preincubated for 10 mins prior to substrate addition measured after 4 mins by FLIPR assay2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID341210Agonist activity at human trace amine associated receptor 1 expressed in RD-HGA16 CHO-K1 cells coexpressed with Galpha16 protein assessed as internal calcium mobilization by calcium 3 assay2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Structure-activity correlations for beta-phenethylamines at human trace amine receptor 1.
AID359911Ratio of IC50 for rat striatum dopamine D2 receptor to IC50 for Wistar rat striatal synaptosomes dopamine transporter-mediated [3H]dopamine uptake1995Journal of natural products, Oct, Volume: 58, Issue:10
Effects of various isoquinoline alkaloids on in vitro 3H-dopamine uptake by rat striatal synaptosomes.
AID1066374Selectivity ratio of EC50 for rat TAAR1 transmembrane domain 6 Met268(6.55)Thr mutant to EC50 for rat wild type TAAR12014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID635293Activation of mouse TAAR1 expressed in human HEK293 cells assessed as accumulation of cAMP after 15 mins2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID1066372Activation of mouse TAAR1 Asp102(3.32)Ala mutant expressed in HEK293 cells assessed as stimulation of cAMP production at 0.0001 to 100 uM after 1 hr by chemiluminescent assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID6406Affinity against 5-hydroxytryptamine receptors in rat fundus model1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Serotonin receptor affinities of psychoactive phenalkylamine analogues.
AID1442401Induction of stimulus generalization in rat trained to discriminate (+)amphetamine assessed as appropriate responding level to training drug by two lever method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID114978Evaluated for the spontaneous motor activity in mice and the mean total activity (MTA) was reported; Expressed as counts/90 min/3 mice1982Journal of medicinal chemistry, May, Volume: 25, Issue:5
A new, potent, conformationally restricted analogue of amphetamine: 2-amino-1,2-dihydronaphthalene.
AID1442370Activity at DAT in rat synaptosomes assessed as release of [3H]DA after 5 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID1131815Induction of rotation in rat with unilateral denervation of caudate nucleus at 1 mg/kg, sc1979Journal of medicinal chemistry, Aug, Volume: 22, Issue:8
N-Alkyl derivatives of (+/-)-alpha-methyldopamine.
AID175692Effective concentration was measured for the release of accumulated [3H]NE from chopped cortex of rat1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Pronounced pharmacological differences arising from minor structural changes in conformationally defined amphetamine analogues. Comparative evaluation of endo- and exo-2-amino- and endo- and exo-2-(methylamino)benzobicyclo[2.2.1]heptene and -benzobicylco[
AID1442371Activity at NET in rat synaptosomes assessed as release of [3H]NE after 30 mins by liquid scintillation counting method2017Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7
The 2014 Philip S. Portoghese Medicinal Chemistry Lectureship: The "Phenylalkylaminome" with a Focus on Selected Drugs of Abuse.
AID118783Compound was tested for cognitive activity by measuring retention for passive avoidance learning in mice at dose 0.15 mg/kg1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Cognition-activating properties of 3-(Aryloxy)pyridines.
AID111824Ability to reverse electroconvulsive shock (ECS) induced amnesia in mice, after administering intraperitoneally, at a dose of 0.31 mg/kg1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Amnesia-reversal activity of a series of N-[(disubstituted-amino)alkyl] -2-oxo-1-pyrrolidineacetamides, including pramiracetam.
AID1581833Substrate activity at human DAT expressed in HEK293 cells preloaded with [3H]-MPP+ assessed as increase in tritium efflux at 3 uM measured every 4 mins by liquid scintillation counting analysis2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Structure-Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters.
AID1066365Activation of rat wild type TAAR1 expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID459600Inhibition of human recombinant MAOB by spectrophotometrically2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID635290Activation of rat TAAR1 expressed in HEK293 cells assessed as accumulation of [3H]cAMP after 1 hr by competitive binding assay2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
AID459598Inhibition of MAOB in rat brain mitochondrial suspension2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
2-Arylthiomorpholine derivatives as potent and selective monoamine oxidase B inhibitors.
AID1597728Half life in human at 10 mg2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Sleep modulating agents.
AID1066361Activation of rat TAAR1 transmembrane domain 7 Asn287(7.39)Tyr mutant expressed in HEK293 cells assessed as stimulation of cAMP production at at 0.0001 to 100 uM after 1 hr by chemiluminescent assay relative to beta-phenylethylamine2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Exploring the determinants of trace amine-associated receptor 1's functional selectivity for the stereoisomers of amphetamine and methamphetamine.
AID353104Ratio of Ki for rat brain NMDA receptor in presence of 100 uM spermine to Ki for rat brain NMDA receptor in absence of spermine2009Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9
NMDA receptor affinities of 1,2-diphenylethylamine and 1-(1,2-diphenylethyl)piperidine enantiomers and of related compounds.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346295Mouse TA1 receptor (Trace amine receptor)2007The Journal of pharmacology and experimental therapeutics, Apr, Volume: 321, Issue:1
Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.
AID1346971Human NET (Monoamine transporter subfamily)2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID1346358Rat TA1 receptor (Trace amine receptor)2001Molecular pharmacology, Dec, Volume: 60, Issue:6
Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor.
AID1346295Mouse TA1 receptor (Trace amine receptor)2007Genes, brain, and behavior, Oct, Volume: 6, Issue:7
The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia.
AID1346358Rat TA1 receptor (Trace amine receptor)2007The Journal of pharmacology and experimental therapeutics, Apr, Volume: 321, Issue:1
Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine.
AID1346963Human DAT (Monoamine transporter subfamily)2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
AID1346375Human TA1 receptor (Trace amine receptor)2008Molecular pharmacology, Sep, Volume: 74, Issue:3
Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor.
AID1346375Human TA1 receptor (Trace amine receptor)2011Bioorganic & medicinal chemistry, Dec-01, Volume: 19, Issue:23
Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,726)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904275 (63.56)18.7374
1990's913 (13.57)18.2507
2000's794 (11.80)29.6817
2010's644 (9.57)24.3611
2020's100 (1.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 110.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index110.14 (24.57)
Research Supply Index8.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index208.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (110.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials697 (9.89%)5.53%
Reviews274 (3.89%)6.00%
Case Studies195 (2.77%)4.05%
Observational3 (0.04%)0.25%
Other5,875 (83.40%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (79)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[C-11]NPA PET-amphetamine in Cocaine Use Disorders (Aim 2) [NCT05011760]Early Phase 130 participants (Anticipated)Interventional2021-01-31Recruiting
An 8 Week Randomized Double Blind Placebo Controlled Multi-site Study Assessing Efficacy and Safety of MYDAYIS® (D-amphetamine / L-amphetamine) for Bipolar Depression [NCT04235686]Phase 290 participants (Anticipated)Interventional2020-07-17Recruiting
A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Con [NCT03200080]Phase 126 participants (Actual)Interventional2017-09-18Terminated(stopped due to New Safety Information)
Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder [NCT02142140]326 participants (Anticipated)Interventional2012-12-31Active, not recruiting
Disentangling Pre- and Postsynaptic Aspects of Amphetamine-induced Sensitization: a Combined [18F]DOPA / [11C]-(+)-PHNO PET Study [NCT03223844]22 participants (Anticipated)Interventional2018-01-01Recruiting
A Randomized, Double-Blind, Double-Dummy, Placebo-, Active-Controlled, 4 Period, 4 Way Crossover Study to Evaluate the Abuse Potential of Manipulated Abuse-Deterrent Dextroamphetamine Sulfate Immediate Release (ADAIR) Formulation Compared to Dextroampheta [NCT04647903]Phase 155 participants (Actual)Interventional2020-10-05Completed
Exploration of Mechanisms of Effects of Prenatal Cocaine Exposure in Young Adults [NCT03606473]Early Phase 113 participants (Actual)Interventional2018-01-24Completed
Effect of D-amphetamine on Reward Functioning [NCT03369015]Phase 168 participants (Actual)Interventional2018-01-24Completed
Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD [NCT02884544]Phase 222 participants (Actual)Interventional2016-08-31Completed
Brain Indices of Stimulant Treatment in Drug-Naive Youth at Risk for Substance Use Disorder [NCT04170738]Phase 444 participants (Anticipated)Interventional2019-11-05Recruiting
[NCT02144415]Phase 180 participants (Actual)Interventional2014-05-31Completed
Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD [NCT01220440]Phase 436 participants (Actual)Interventional2006-01-31Completed
Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder [NCT02210728]200 participants (Anticipated)Interventional2006-04-30Active, not recruiting
Imaging of Cortical Dopamine Transmission in Cocaine Dependence [NCT03349606]Early Phase 130 participants (Anticipated)Interventional2010-06-02Completed
Vyvanse and Glucose Intolerance in Children With ADHD and Obesity [NCT01017263]Phase 414 participants (Actual)Interventional2009-12-31Terminated(stopped due to Due very high screen fail rate, pre study feasibility not consistent with screened population.)
Randomized Study to Evaluate Strategies to Address Cognitive Fog in Long-COVID-19 Patients [NCT05597722]Phase 47 participants (Actual)Interventional2023-04-04Terminated(stopped due to Due to the evolving nature of COVID-related cognitive fog, it was determined that the study would be terminated at this time. The team agreed that it isn't feasible to collect enough data to evaluate the efficacy of the treatments.)
The Reinforcing Mechanisms of Smoking in Adult ADHD [NCT00573859]Phase 1/Phase 227 participants (Actual)Interventional2006-09-30Completed
Efficacy and Safety of 24 Weeks Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder With Comorbid Opioid Use Disorder - A Multicenter Randomized, Double-blind, Placebo-controlled Study [NCT05529927]Phase 2204 participants (Anticipated)Interventional2024-03-31Not yet recruiting
Double-blind Trial of Acute and Intermediate-term Dextro-amphetamine Versus Caffeine Augmentation in Treatment Resistant Obsessive Compulsive Disorder (OCD) [NCT00363298]24 participants (Actual)Interventional2006-08-31Completed
A Randomized, Double-Blind, Single-Site Phase II 2-Arm Study to Compare the Safety and Preliminary Efficacy of Manualized MDMA-Assisted Therapy to Low Dose D-Amphetamine Assisted Therapy in Veterans For The Treatment of Moderate to Severe PTSD [NCT05790239]Phase 240 participants (Anticipated)Interventional2023-10-31Not yet recruiting
Targeting Anhedonia in Cocaine Use Disorder - Treatment Study [NCT02773212]Phase 280 participants (Anticipated)Interventional2017-02-01Recruiting
Endocrine and Emotional Effects of Lisdexamfetamine and d- Amphetamine: a Placebo-controlled Study in Healthy Subjects (LisDexStudy) [NCT02668926]Phase 124 participants (Actual)Interventional2016-05-31Completed
Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine, a Post-authorization Safety Study [NCT04132557]430,000 participants (Actual)Observational2019-10-09Completed
Pharmacokinetics of New Dexamphetamine Sustained Release Tablets and the Clinical Validation of Measuring Dexamphetamine in Dried Blood Spots [NCT02768441]Early Phase 112 participants (Actual)Interventional2016-11-01Completed
A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). [NCT00152022]Phase 3412 participants Interventional2005-04-25Completed
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]5,000 participants (Anticipated)Observational2020-03-05Recruiting
A Single-Blind, Randomized Study of the Comparative Drug Likeability and Pharmacokinetics of Vyvanse™ and ADDERALL XR® When Administered as a Solution [NCT00776555]Phase 13 participants (Actual)Interventional2008-11-21Terminated(stopped due to The study was stopped by the sponsor based on a non-safety related business priority decision.)
Adjunctive Treatment With Divalproex or Risperidone for Aggression Refractory to Stimulant Monotherapy Among Children With ADHD [NCT00794625]Phase 4270 participants (Anticipated)Interventional2008-11-30Recruiting
A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder [NCT02566824]Phase 4216 participants (Anticipated)Interventional2010-10-31Recruiting
A Pilot, Randomized, Double-Blind, Active-Controlled, 2-Treatment, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Abuse Liability of Dextroamphetamine Sulfate From an Abuse-Deterrent Immediate-Release Formulation (ADAIR) [NCT04232644]Phase 116 participants (Actual)Interventional2019-05-27Completed
Smoked Marijuana Discrimination and Marijuana Choice in Humans: A Laboratory Mode [NCT00943930]29 participants (Actual)Observational2009-04-30Completed
The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study [NCT02788851]70 participants (Anticipated)Interventional2016-04-30Active, not recruiting
Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia [NCT03999190]0 participants (Actual)Observational2019-07-31Withdrawn(stopped due to investigational radiotracer was not approved)
Bariatric Surgery and Pharmacokinetics Dexamphetamine: BAR-MEDS Dexamphetamine [NCT03460353]12 participants (Anticipated)Observational2016-11-02Recruiting
Amphetamine-Enhanced Stroke Recovery [NCT01905371]Phase 299 participants (Actual)Interventional2001-04-30Completed
General Evaluation of Eligibility for Substance Abuse/Dependence Research [NCT00439049]7,500 participants (Anticipated)Observational2005-10-31Recruiting
The Difference in Pharmacodynamic and Pharmacokinetic Profiles Between Tentin and Magisterial Dexamfetamine in Adults With Attention Deficit Hyperactivity Disorder, a Double Blinded Randomised Crossover-controlled Trial [NCT05621174]26 participants (Anticipated)Interventional2023-04-14Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD [NCT01711021]Phase 2110 participants (Actual)Interventional2012-10-31Completed
A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence [NCT00630682]Phase 260 participants (Actual)Interventional2006-09-30Completed
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications [NCT00697138]Phase 146 participants (Actual)Interventional2006-06-30Completed
Lis-dexamphetamine (LDX/SPD489)as a Treatment for Smoking Cessation in Nicotine Dependent Individuals With ADHD [NCT00736255]32 participants (Actual)Interventional2007-12-31Completed
A Phase III, Randomized, Double-blind, Multi-center, Placebo-Controlled, Parallel-Group, Safety and Efficacy Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). [NCT00150579]Phase 3240 participants Interventional2005-01-27Completed
Dextroamphetamine as an Adjunct in Cocaine/Opiate Dependent Patients [NCT00000306]Phase 2140 participants Interventional1994-09-30Completed
Dextroamphetamine Treatment for Comorbid Cocaine Dependence and ADHD [NCT00514202]Phase 25 participants (Actual)Interventional2007-08-31Terminated(stopped due to Investigator left UTHSC-Houston)
Double-Blind, Placebo-Controlled Trial of Flexible Dose Divalproex Sodium Adjunctive to Stimulant Treatment for Aggressive Children With Attention-Deficit Hyperactivity Disorder [NCT00228046]Phase 440 participants (Anticipated)Interventional2004-01-31Completed
A Pilot Study of Treatment for Refractory Depression With Sequential Trials of Tranylcypromine, Tranylcypromine Plus Dextroamphetamine, Tranylcypromine Plus Triiodothyronine. [NCT00296686]Phase 431 participants (Actual)Interventional2001-09-30Terminated(stopped due to Study is no longer funded.)
Spectroscopic Imaging of GABA and Glutamate/Glutamine in Healthy Volunteers at 4T: A Double Blind, Crossover Drug Challenge Study [NCT01577706]7 participants (Actual)Interventional2013-06-30Terminated(stopped due to lack of enrollment)
A Phase II, Randomized, Double-Blind, Multi-center, Placebo-controlled, Crossover Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) [NCT00202605]Phase 272 participants Interventional2005-09-29Completed
Pharmacotherapy for Cocaine Dependence - 1 [NCT00218348]Phase 2186 participants (Actual)Interventional2003-09-30Completed
Amphetamine Cocaine Interaction Study [NCT00000305]Phase 10 participants InterventionalTerminated(stopped due to Original P.I. left the institution)
Adderall-XR Versus Concerta For Cancer Treatment-Related Neurocognitive Sequelae And Depression In Pediatric Patients: A Randomized Phase II Study [NCT00069927]Phase 212 participants (Actual)Interventional2003-08-31Terminated(stopped due to Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility)
A Phase III, Multi-center, 12-month, Open-label Safety Study of SPD465 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD). [NCT00152035]Phase 3505 participants (Actual)Interventional2005-03-10Completed
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis [NCT02634684]Phase 282 participants (Actual)Interventional2014-07-01Completed
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy Humans [NCT03103750]Phase 124 participants (Actual)Interventional2017-08-15Completed
The Role of the Dopaminergic Brain Reward System in Apathy Associated With Alzheimer's Disease [NCT00254033]Phase 440 participants Interventional2003-10-31Completed
D-amphetamine-Cocaine Behavioral Intervention [NCT00000308]Phase 254 participants (Actual)Interventional1995-09-30Completed
Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer [NCT02383043]Early Phase 118 participants (Actual)Interventional2015-02-01Completed
Neurobehavioral Mechanisms of Cocaine Choice [NCT04296006]Early Phase 118 participants (Anticipated)Interventional2021-01-15Recruiting
Dextroamphetamine as an Adjunct in Cocaine Treatment [NCT00000304]Phase 2120 participants (Actual)Interventional1997-08-31Completed
Objectifying the Day-time Response Variation of (Lis)Dexamphetamine in Adults With ADHD [NCT04946461]16 participants (Actual)Observational2021-07-01Completed
Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With DESR Traits: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial [NCT01399827]Phase 22 participants (Actual)Interventional2012-02-29Completed
Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls [NCT02203786]Phase 260 participants (Actual)Interventional2009-09-30Completed
Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers [NCT02348385]49 participants (Actual)Observational2012-12-31Completed
Hypomania, Amphetamine, and Preferences for Sweets [NCT03810703]Phase 193 participants (Actual)Interventional2017-02-09Completed
Attention Management Trial for Children With FASD - a N-of-1 Control Trial of Prescribed Stimulants for ADHD in FASD [NCT04968522]Phase 420 participants (Anticipated)Interventional2022-02-14Recruiting
Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase [NCT02514044]Phase 210 participants (Actual)Interventional2015-03-31Completed
Stimulant Enhancement of Well-Being Therapy for Depression [NCT01478113]5 participants (Actual)Interventional2012-02-29Terminated(stopped due to PI left the institution and was no funding to continue study.)
A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial [NCT02363075]Phase 358 participants (Anticipated)Interventional2013-04-30Recruiting
Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion [NCT01699607]10 participants (Actual)Interventional2012-06-30Completed
A Preliminary Investigation of Individual Differences in Subjective Responses to D-amphetamine, Alcohol, and Delta-9-tetrahydrocannabinol [NCT02485158]28 participants (Actual)Interventional2013-07-31Completed
Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines [NCT03772314]Phase 244 participants (Actual)Interventional2019-04-15Completed
Pharmacotherapy Dosing Regimen (Cocaine Dependence Population) [NCT00218062]Phase 273 participants (Actual)Interventional2006-03-31Completed
Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing [NCT03019822]Early Phase 128 participants (Actual)Interventional2017-02-01Completed
Amphetamine Withdrawal Paradigm in Humans [NCT01215929]Phase 235 participants (Actual)Interventional2009-10-31Completed
Monoamine Contributions to Neurocircuitry in Eating Disorders [NCT02020408]Phase 488 participants (Actual)Interventional2011-05-31Completed
Dopaminergic Neuromodulation of Decision Making in Young and Middle-Aged Adults [NCT03512171]Phase 165 participants (Actual)Interventional2016-03-31Completed
A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation [NCT02204410]Phase 421 participants (Actual)Interventional2014-07-31Completed
A Randomized, Placebo- and Comparator-controlled, Double-blind, Multiple (Ascending) Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Subjects [NCT02515955]Phase 176 participants (Actual)Interventional2015-08-31Completed
Stimulant Medication Effects on Auditory Sensitivity and Acoustic Reflex in Adolescents With ADHD [NCT04577417]70 participants (Actual)Observational2020-09-13Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00218062 (5) [back to overview]Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples
NCT00218062 (5) [back to overview]Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report
NCT00218062 (5) [back to overview]Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment
NCT00218062 (5) [back to overview]Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment
NCT00218062 (5) [back to overview]Retention as Indicated by the Number of Participants Who Remained in the Study
NCT00363298 (2) [back to overview]Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2
NCT00363298 (2) [back to overview]Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score
NCT00573859 (3) [back to overview]The Effects of ADHD Medication Versus Placebo on Cotinine Levels
NCT00573859 (3) [back to overview]The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.
NCT00573859 (3) [back to overview]The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission.
NCT00736255 (7) [back to overview]N-back Test Proportion Correct Across 4 Load Factors
NCT00736255 (7) [back to overview]Smoking Rates
NCT00736255 (7) [back to overview]Continuous Performance Test (CPT) Reaction Time Standard Error
NCT00736255 (7) [back to overview]The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit.
NCT00736255 (7) [back to overview]ADHD Conners' Adult ADHD Rating Scales (CAARS) Self-Report and Observer Short Forms
NCT00736255 (7) [back to overview]Clinician Rated Clinical Global Impressions of Improvement Scale (CGI-I)
NCT00736255 (7) [back to overview]Continuous Performance Test (CPT) Commission Errors
NCT01215929 (1) [back to overview]Measure of Methamphetamine Withdrawal
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale
NCT01399827 (5) [back to overview]Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale
NCT01399827 (5) [back to overview]Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales
NCT01577706 (7) [back to overview]Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01577706 (7) [back to overview]Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01577706 (7) [back to overview]Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01577706 (7) [back to overview]Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01577706 (7) [back to overview]Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01577706 (7) [back to overview]Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01577706 (7) [back to overview]Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge
NCT01699607 (1) [back to overview]Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.
NCT01711021 (7) [back to overview]Conners Parent Rating Scale Revised Short Form (CPRS-R:S) Total Scores From Week 6 and Week 7
NCT01711021 (7) [back to overview]Duration of Effect for d-Amphetamine and Placebo Treatment
NCT01711021 (7) [back to overview]Number of Responders Evaluated by Clinical Global Impression (CGI-I) Scale by Treatments From the Double-blind Treatment Period
NCT01711021 (7) [back to overview]Onset of Efficacy Measured by Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score
NCT01711021 (7) [back to overview]Permanent Product Measure of Performance (PERMP) Scores Including PREMP-C and PREMP-A From Different Timepoints Post-dose
NCT01711021 (7) [back to overview]Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score During the Double-Blind Treatment Period
NCT01711021 (7) [back to overview]Change in the Clinician-rated Scale of ADHD Symptoms Based on DSM-IV-TR Criteria (ADHD-RS-IV).
NCT02020408 (2) [back to overview]Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration
NCT02020408 (2) [back to overview]5-HT Transporter Binding as Measured During the PET Scan
NCT02203786 (6) [back to overview]Cognitive Task Performance
NCT02203786 (6) [back to overview]Speed of Play on Slot Machine Game
NCT02203786 (6) [back to overview]Betting Behaviour in Laboratory-based Slot Machine Game
NCT02203786 (6) [back to overview]Winnings on Slot Machine Upon Completion of Game
NCT02203786 (6) [back to overview]Diastolic Blood Pressure (DBP)
NCT02203786 (6) [back to overview]Subjective Reinforcement Self-report Scales
NCT02204410 (2) [back to overview]Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent)
NCT02204410 (2) [back to overview]Clinical Global Impression (CGI) Improvement for Deficient Emotional Self-Regulation (DESR)
NCT02348385 (1) [back to overview]Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration
NCT02383043 (1) [back to overview]The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration
NCT02485158 (14) [back to overview]Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion
NCT02485158 (14) [back to overview]Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration
NCT02514044 (3) [back to overview]Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery
NCT02514044 (3) [back to overview]Percent Change in Language Quotient as Assessed by the Western Aphasia Battery
NCT02514044 (3) [back to overview]Percent Change in Blood Pressure
NCT02634684 (3) [back to overview]Targeted Cognitive Training (TCT): PositScience, Inc.
NCT02634684 (3) [back to overview]Prepulse Inhibition (PPI)
NCT02634684 (3) [back to overview]MATRICS Consensus Cognitive Battery Performance (MCCB)
NCT03810703 (1) [back to overview]"Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ)."

Medication Compliance as Indicated by Percentage of Riboflavin-positive Urine Samples

(NCT00218062)
Timeframe: 16 weeks

Intervention% of riboflavin-positive urine samples (Number)
D-Amphetamine 60mg + Therapy67.1
Modafinil 400mg + Therapy70
Modafinil 200mg + D-Amphetamine 30mg + Therapy76.8
Placebo + Therapy66.7

[back to top]

Medication Compliance as Indicated by Percentage of Pills Taken According to Self-report

(NCT00218062)
Timeframe: 16 weeks

Interventionpercentage of pills taken (Number)
D-Amphetamine 60mg + Therapy80.2
Modafinil 400mg + Therapy34.5
Modafinil 200mg + D-Amphetamine 30mg + Therapy65.8
Placebo + Therapy73.2

[back to top]

Cocaine Use as Assessed by the Treatment Effectiveness Score (TES), Which is the Total Number of Cocaine-negative Urines During Treatment

(NCT00218062)
Timeframe: 16 weeks

Interventionnumber of cocaine negative urines (Mean)
D-Amphetamine 60mg + Therapy9.25
Modafinil 400mg + Therapy6.09
Modafinil 200mg + D-Amphetamine 30mg + Therapy6
Placebo + Therapy4.91

[back to top]

Retention as Indicated by the Number of Participants Who Completed 16 Weeks of Treatment

(NCT00218062)
Timeframe: 16 weeks

Interventionparticipants (Number)
D-Amphetamine 60mg + Therapy7
Modafinil 400mg + Therapy4
Modafinil 200mg + D-Amphetamine 30mg + Therapy3
Placebo + Therapy3

[back to top]

Retention as Indicated by the Number of Participants Who Remained in the Study

(NCT00218062)
Timeframe: 16 weeks

Interventionparticipants (Number)
D-Amphetamine 60mg + Therapy7
Modafinil 400mg + Therapy4
Modafinil 200mg + D-Amphetamine 30mg + Therapy3
Placebo + Therapy3

[back to top]

Number of Subjects With Clinical Global Impressions Scale - Improvement (CGI-I) Score of 1 or 2

Clinical Global Impressions Scale Improvement Score = 1 (very much improved), or 2 (much improved). Additional possible scale scores are 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse) and 7 (very much worse). (NCT00363298)
Timeframe: At end of week 5, except 1 d-amphetamine subject rated at end of week 2

Interventionparticipants (Number)
D-amphetamine6
Caffeine Pills7

[back to top]

Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) Score

"Yale-Brown Obsessive-Compulsive Scale score by blinded investigator in direct interview. The scale score is the sum of ten items (5 for obsessions and 5 for compulsions: time occupied, degree of interference with functioning, degree of distress, effort to resist the symptom, success in resisting), each rated from 0 to 4, with higher scores indicating more severe OCD. Maximum score is 40. Scores of 14 and below are often described as subclinical, though patients with these scores may still exhibit troubling symptoms and mild to moderate distress. A total score of 8 or less is often termed remission. A decrease in total score from baseline to endpoint of either 25% or 35% is often used as a responder criterion in clinical trials." (NCT00363298)
Timeframe: At end of week 5, except 1 d-amphetamine subject rated at end of week 2

Interventionunits on a scale (Mean)
D-amphetamine13.3
Caffeine Pills13.0

[back to top]

The Effects of ADHD Medication Versus Placebo on Cotinine Levels

Salivary cotinine was measured across two days on ADHD medication versus two days on placebo. (NCT00573859)
Timeframe: 4 days

Interventionng/ml (Mean)
ADHD medicationPlacebo
ADHD Medication Versus Placebo180.7274.0

[back to top]

The Interacting Effects of Smoking and Abstinence With ADHD Medication and Placebo on Nicotine Withdrawal Measured by the Shiffman-Jarvik Withdrawal Questionnaire.

The Shiffman-Jarvik withdrawal questionnaire measures nicotine withdrawal and was completed after each CPT assessment. The questionnaire consists of 25 items using 8-point scales. Total scores range from 0 to 200 and higher scores reflect higher levels of nicotine withdrawal. (NCT00573859)
Timeframe: 4 days

Interventionscores on a scale (Median)
ADHD medication + SmokingADHD medication + AbstinencePlacebo + SmokingPlacebo + Abstinence
ADHD Medication Versus Placebo92.791.397.0102.0

[back to top]

The Interacting Effects of Smoking and Overnight Abstinence With ADHD Medication and Placebo on Continuous Performance Task (CPT) Errors of Omission.

In the morning of each monitoring day, approximately 60 minutes after medication or placebo pill administration, participants were asked to either abstain from smoking or smoke their first cigarette of the day 5 minutes prior to starting the CPT. (NCT00573859)
Timeframe: 4 days

Interventionerrors (Mean)
ADHD medication + SmokingADHD medication + AbstinencePlacebo + SmokingPlacebo + Abstinence
ADHD Medication Versus Placebo0.401.081.002.8

[back to top]

N-back Test Proportion Correct Across 4 Load Factors

This is measured by the N-Back test, a cognitive functioning, including working memory test. The test is designed with 4 Load Factors, where the current stimulus matches the one from 'n' steps back or prior in the sequence. The load factor n is adjusted so there is a 'O-back' (i.e. 'n-0'), '1-back' (i.e. 'n-1'), '2-back' (i.e. 'n-2'), and '3-back' (i.e. 'n-3'). When the correct stimulus appears on the screen, the participant then responds on the computer. Missing the stimulus decreases the proportion correct. (NCT00736255)
Timeframe: Randomization, Visits 1 (day 4), 2 (day 7), 3 (day 11), 4 (day 14), 5 (day 18), 6 (day 21), 7 (day 25), 8 (day 28)

,
Interventionproportion correct to stimuli response (Mean)
Randomization (Visit 0) 0-back _%corRandomization (Visit 0) 1-back _%corRandomization (Visit 0) 2-back _%corRandomization (Visit 0) 3-back _%corVisit 1 (day 4) 0-back _%corVisit 1 (day 4) 1-back _%corVisit 1 (day 4) 2-back _%corVisit 1 (day 4) 3-back _%corVisit 2 (day 7) 0-back _%corVisit 2 (day 7) 1-back _%corVisit 2 (day 7) 2-back _%corVisit 2 (day 7) 3-back _%corVisit 3 (day 11) 0-back _%corVisit 3 (day 11) 1-back _%corVisit 3 (day 11) 2-back _%corVisit 3 (day 11) 3-back _%corVisit 4 (day 14) 0-back _%corVisit 4 (day 14) 1-back _%corVisit 4 (day 14) 2-back _%corVisit 4 (day 14) 3-back _%corVisit 5 (day 18) 0-back _%corVisit 5 (day 18) 1-back _%corVisit 5 (day 18) 2-back _%corVisit 5 (day 18) 3-back _%corVisit 6 (day 21) 0-back _%corVisit 6 (day 21) 1-back _%corVisit 6 (day 21) 2-back _%corVisit 6 (day 21) 3-back _%corVisit 7 (day 25) 0-back _%corVisit 7 (day 25)1-back _%corVisit 7 (day 25) 2-back _%corVisit 7 (day 25) 3-back _%corVisit 8 (day 28) 0-back _%corVisit 8 (day 28) 1-back _%corVisit 8 (day 28) 2-back _%corVisit 8 (day 28) 3-back _%cor
LDX and NRT0.960.940.960.840.950.900.890.800.930.900.860.810.890.890.890.840.930.910.900.901.000.980.990.880.930.930.900.890.990.990.970.910.930.980.920.91
NRT and Placebo1.000.990.950.801.000.990.960.830.920.950.920.810.990.990.950.900.990.990.950.890.990.990.980.921.000.980.960.870.990.990.950.880.990.980.950.84

[back to top]

Smoking Rates

Smoking rates, measured as self-reported cigarettes/day. (NCT00736255)
Timeframe: Randomization, visits 1 (day 4), 2 (day 7), 3 (day 11), 4 (day 14), 5 (day 18), 6 (day 21), 7 (day 25), 8 (day 28)

,
InterventionCigarettes smoked per day (Mean)
Randomization (Visit 0)Visit 1 (day 4)Visit 2 (day 7)Visit 3 (day 11)Visit 4 (day 14)Visit 5 (day 18)Visit 6 (day 21)Visit 7 (day 25)Visit 8 (day 28)
LDX and NRT6.433.903.162.752.983.083.944.384.15
NRT and Placebo8.142.591.832.232.102.922.672.332.91

[back to top]

Continuous Performance Test (CPT) Reaction Time Standard Error

The CPT is a measure of both vigilance/sustained attention and response inhibition, has good normative data and has been shown to be sensitive to the effects of stimulants. Reaction time variability and commission errors - measures of attentional control and response inhibition have been shown to be sensitive in discriminating individuals with ADHD on active medication versus placebo. (NCT00736255)
Timeframe: Randomization, Visits 1 (day 4), 2 (day 7), 3 (day 11), 4 (day 14), 5 (day 18), 6 (day 21), 7 (day 25), 8 (day 28)

,
InterventionReaction time in seconds (Mean)
Randomization (Visit 0)Visit 1 (day 4)Visit 2 (day 7)Visit 3 (day 11)Visit 4 (day 14)Visit 5 (day 18)Visit 6 (day 21)Visit 7 (day 25)Visit 8 (day 28)
LDX and NRT5.375.525.424.974.835.544.645.294.86
NRT and Placebo4.614.685.055.014.795.154.975.735.08

[back to top]

The Number of Subjects in Each Treatment Group Exhibiting Sustained, 4-week Smoking Abstinence, Defined as CO Levels <= 4 Ppm for Each Post-quit Study Visit.

The primary outcome measure was the proportion of subjects in each treatment group exhibiting sustained, 4-week smoking abstinence, defined as CO levels <= 4 ppm for each post-quit study visit. Subjects who dropped from the study for any reason were considered to have lapsed. (NCT00736255)
Timeframe: 4 weeks

Interventionparticipants (Number)
LDX and NRT5
NRT and Placebo3

[back to top]

ADHD Conners' Adult ADHD Rating Scales (CAARS) Self-Report and Observer Short Forms

"T-scores derived from compiled ADHD symptoms from two forms. Specifically the t-scores for the DSM-IV Total subscale, representing ADHD symptoms. This is conducted by the participant and clinician at randomization, visits 2 and 4 (i.e. dose titration visits), Visit 6 (i.e. monitoring visit), and Visit 8 (i.e. final/end of study visit).~The following describes severity of the ADHD symptoms (based upon T-Score):~70+ = Very Much Above Average 66-70 = Much Above Average 61-65 = Above Average 56-60 = Slightly Above Average 45-55 = Average 30-44 = Below Average (Low scores are good)" (NCT00736255)
Timeframe: Randomization, Visits 2 (day 7), 4 (day 14), 6 (day 21), 8 (day 28)

,
InterventionT-score on a scale (Mean)
Randomization (Visit 0)Visit 2 (day 7)Visit 4 (day 14)Visit 6 (day 21)Visit 8 (day 28)
LDX and NRT67.1363.0758.6252.8354.00
NRT and Placebo68.0864.6265.2563.4261.92

[back to top]

Clinician Rated Clinical Global Impressions of Improvement Scale (CGI-I)

Measures clinician's perception of patient improvement at the time of assessment compared with the start of treatment. 1-Very Much Improved through 7-Very Much Worse. (NCT00736255)
Timeframe: Visits 2 (day 7), 4 (day 14), 6 (day 21), 8 (day 28)

,
Interventionscore on a scale (Mean)
Visit 2 (day 7) CGI-IVisit 4 (day 14) CGI-IVisit 6 (day 21) CGI_IVisit 8 (day 28) CGI-I
LDX and NRT2.882.732.292.00
NRT and Placebo3.503.383.313.15

[back to top]

Continuous Performance Test (CPT) Commission Errors

The CPT is a measure of both vigilance/sustained attention and response inhibition, has good normative data and has been shown to be sensitive to the effects of stimulants. Reaction time variability and commission errors - measures of attentional control and response inhibition have been shown to be sensitive in discriminating individuals with ADHD on active medication versus placebo. (NCT00736255)
Timeframe: Randomization, Visits 1 (day 4), 2 (day 7), 3 (day 11), 4 (day 14), 5 (day 18), 6 (day 21), 7 (day 25), 8 (day 28)

,
InterventionErrors of Commission (Mean)
Randomization (Visit 0)Visit 1 (day 4)Visit 2 (day 7)Visit 3 (day 11)Visit 4 (day 14)Visit 5 (day 18)Visit 6 (day 21)Visit 7 (day 25)Visit 8 (day 28)
LDX and NRT15.2913.2913.4414.5013.1315.0012.3614.6414.92
NRT and Placebo12.4310.7110.8610.7911.0811.1512.1511.7711.23

[back to top]

Measure of Methamphetamine Withdrawal

Total score on the Methamphetamine Withdrawal Assessment scale (MAWA) based on DSMIV criteria for amphetamine withdrawal. This questionnaire is comprised of 13 items which describe symptoms associated with the cessation of chronic amphetamine use for which participants indicate severity on a 4-point scale. The minimum score indicating no methamphetamine withdrawal symptoms is 0 and the maximum score is 4 indicating that a patient has the most severe withdrawal symptom related to that question. The subscales are the 13 questions and the total score is the sum of all the scores for the 13 items on the scale. The range minium and better outcome is a lower score. The range is from 0-52. The worse outcome is reflected in a higher score. (NCT01215929)
Timeframe: at the end of week 4

Interventionunits on a scale (Least Squares Mean)
Dextroamphetamine3.7283
Placebo10.056

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on Adult ADHD Investigator Rating Scale (AISRS) Total Score

"The Adult ADHD Investigator Rating Scale (AISRS) measures ADHD symptoms in adults. This scale is an investigator rated scale. Higher scores on this scale indicate more severe ADHD-like symptoms. Patients symptoms are rated as never, rarely, sometimes, often, or very often by the investigator. Total score ranges from 0 to 54. T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement." (NCT01399827)
Timeframe: baseline to 12 weeks

InterventionT-Score (Number)
Omega-3 Fatty Acids-14
Placebo-23

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on Clinical Global Impression (CGI) Scale

The Clinical Global Impression (CGI) is a 3-item observer-rated scale that measures illness severity (CGIS), global improvement or change (CGIC) and therapeutic response (CGIE). Scores range from 0 to 7 on each subscale. Total scores range from 0 to 21. T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement. (NCT01399827)
Timeframe: baseline to 12 weeks

InterventionT-Score (Number)
Omega-3 Fatty Acids5
Placebo1

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on the Global Assessment of Functioning (GAF) Scale

The Global Assessment of Functioning (GAF) scale is used to rate how serious a mental illness may be. Lower scores on this scale indicate a lower level of functioning and higher severity of symptoms. Total scores range from 0 to 100. (NCT01399827)
Timeframe: baseline to 12 weeks

Interventionunits on a scale (Number)
Omega-3 Fatty Acids11
Placebo8

[back to top]

Mean Change From Baseline to Endpoint on the BRIEF-A Emotional Control Scale

The BRIEF-A is a 75-item questionnaire that assesses and adult's cognitive, emotional, and behavioral functions within the past month. The subject rates each question on a 3-point scale (1=Never, 2=Sometimes, 3=Often). Raw scores are calculated and used to generate T-scores for 8 scales (Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials), 2 summary index scales (Behavioral Regulation Index and Metacognition Index), and one scale reflecting overall functioning (Global Executive Composite). T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement. (NCT01399827)
Timeframe: Baseline to 12 weeks

InterventionT-Score (Number)
Omega-3 Fatty Acids-7
Placebo-33

[back to top]

Efficacy Measured by Mean Change From Baseline to Endpoint on BRIEF-A Subscales

The BRIEF-A is a 75-item questionnaire that assesses and adult's cognitive, emotional, and behavioral functions within the past month. The subject rates each question on a 3-point scale (1=Never, 2=Sometimes, 3=Often). Raw scores are calculated and used to generate T-scores for 8 scales (Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials), 2 summary index scales (Behavioral Regulation Index and Metacognition Index), and one scale reflecting overall functioning (Global Executive Composite). T-scores range from 30 to 100, with scores ≥65 indicating clinical impairment. A reduction in score indicates improvement. (NCT01399827)
Timeframe: baseline to 12 weeks

,
Interventionunits on a scale (Number)
Change in BRIEF-A Inhibit Scale T-Scores from BaseChange in BRIEF-A Shift Scale T-Scores from BaseliChange in BRIEF-A Self Monitor Scale T-Scores fromChange in BRIEF-A Initiate Scale T-Scores from BasChange in BRIEF-A Working Memory Scale T-Scores frChange in BRIEF-A Plan/Organize Scale T-Scores froChange in BRIEF-A Task Monitor Scale T-Scores fromChange in BRIEF-A Organization of Materials ScaleChange in BRIEF-A BRI Scale T-Scores from BaselineChange in BRIEF-A MI Scale T-Scores from BaselineChange in BRIEF-A GEC Scale T-Scores from Baseline
Omega-3 Fatty Acids-1400-17-11-11-5-6-7-12-11
Placebo-28-13-13-9-30-19-32-22-29-46-29

[back to top]

Right Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam-9.443.0333.5817.08-0.8235.96
Dextroamphetamine38.7867.4137.9221.02-5.9614.20
Placebo18.63-3.97-1.53-9.8811.4610.15

[back to top]

Left Basal-Ganglia: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam43.1743.0944.266.573.53-4.57
Dextroamphetamine5.2817.0614.6813.4020.1922.34
Placebo-2.912.1115.59-0.582.665.10

[back to top]

Left Temporal: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam4.3813.4458.4914.5532.8119.68
Dextroamphetamine6.361.3418.24-6.707.53-20.20
Placebo-10.24-13.82-8.77-10.553.83-2.03

[back to top]

Left Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam23.5739.2923.3012.72-2.1010.79
Dextroamphetamine-12.518.2613.6317.755.4524.16
Placebo-6.80-2.6310.014.47-6.3215.44

[back to top]

Parieto-Occipital: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam-0.511.9021.954.6410.7818.83
Dextroamphetamine39.69-10.2922.35-17.3336.387.97
Placebo6.09-1.6024.542.1521.7633.46

[back to top]

Right Temporal: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam-1.4524.2931.06-4.8623.3419.53
Dextroamphetamine2.09-23.1730.2318.5270.8831.58
Placebo14.9321.2648.95-13.9110.8526.78

[back to top]

Right Thalamus: Percent Change in GABA Levels After an Acute Drug Challenge

"The primary goal of this study is to assess the efficacy of an advanced spectroscopic imaging protocol in detecting changes in the levels of brain GABA in response to an acute drug challenge.~GABA levels are expressed as a ratio to total creatinine: GABA/Cr percent change = 100*(later timepoint - earlier timepoint) / earlier timepoint" (NCT01577706)
Timeframe: from 45 minutes post-dose to 102 minutes post-dose in 19-minute intervals (4 time points at t1: 45, t2: 64, t3: 83, t4: 102 minutes post-dose)

,,
Interventionpercent change (Median)
t1 to t2: 45min-64mint1 to t3: 45min-83mint1 to t4: 45min-102mint2 to t3: 64min-83mint3 to t4: 83min-102mint2 to t4: 64min-102min
Alprazolam2.7219.204.5416.51-1.7812.12
Dextroamphetamine-3.6114.6330.2314.951.6015.51
Placebo6.557.268.39-7.132.8712.69

[back to top]

Change in Dopamine Levels at Baseline and After Amphetamine Administration as Measured by Percent Change in PET Tracer Binding Potential.

PET images will be obtained in subjects at baseline and after amphetamine administration. Dopamine release will be measured as a percent change in binding potential. Increased dopamine release will result in decreased radiotracer binding because dopamine will displace the radiotracer. (NCT01699607)
Timeframe: first 90 minute scan at baseline, second 90 minute scan start 150 minutes post amphetamine administration

Interventionpercent change in binding potential (Mean)
Smoking Subjects-21
Nonsmoking Subjects-29

[back to top]

Conners Parent Rating Scale Revised Short Form (CPRS-R:S) Total Scores From Week 6 and Week 7

"The CPRS-R:S evaluates problem behaviors as reported by the parent or alternative caregivers. The CPRS-R:S total score comprises 27 items and covers a subset of the subscales and items on the long parent form. The score ranges from 0-81 calculated from summed subscales scores. Higher score is considered a worse outcome for ADHD patients.~Note: Week 6 is the first week of the double-blind treatment period, week 7 is the second week of the double-blind treatment period." (NCT01711021)
Timeframe: Combined analysis by treatment groups from week 6 and week 7 (averaged)

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch23.5
Placebo Patch39.5

[back to top]

Duration of Effect for d-Amphetamine and Placebo Treatment

Duration of Effect is the difference between the End of Effect and Onset of Effect in hours, where End of Effect is the first time point after Onset of Effect at which the 50% reduction in SKAMP total score from pre-dose is not observed. (NCT01711021)
Timeframe: Duration of Effect was from onset (2 hours post-dose) and up to 12 hours post-dose (p<0.001)

InterventionHours (Least Squares Mean)
d-Amphetamine Transdermal Patch2.6
Placebo Patch1.7

[back to top]

Number of Responders Evaluated by Clinical Global Impression (CGI-I) Scale by Treatments From the Double-blind Treatment Period

"The CGI scale permits a global evaluation of the subject's improvement over time. During the Dose Optimization Period and the Double-Blind Treatment Period, the investigator assessed the subject's improvement relative to symptoms prior to dosing, using the CGI-I Scale.~For CGI-I scale, the responders are defined as subjects achieving a score of~Very much improved or~Much improved or~The non-responders are defined as subjects achieving a score of~Minimally improved on the clinician-rated CGI global improvement item or~No change or~Minimally worse or~Much worse or~Very much worse~Then the number of responders are calculated by treatment arms. Note: Week 6 is the first week of the double-blind treatment period, week 7 is the second week of the double-blind treatment period." (NCT01711021)
Timeframe: the double-blind treatment period

InterventionParticipants (Count of Participants)
d-Amphetamine Transdermal Patch89
Placebo Patch25

[back to top]

Onset of Efficacy Measured by Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score

"Onset of efficacy defined as the time of the first assessment time showing statistical significance between d-ATS and placebo. The time point for the reported data are SKAMP scores (LS mean) from 2 hours post-dose.~The SKAMP total score comprises all 13 items. The SKAMP was designed for independent observers to rate 13 items representing 2 factors of classroom behavior: attention (SKAMP-A) and deportment (SKAMP-D), as well as quality of work. Items are specific to place (classroom setting) & time (during a typical classroom period), & the scale is used to assess multiple ratings taken within a day. Scores range from 0-78 with higher scores indicating worse impairment." (NCT01711021)
Timeframe: Onset of efficacy defined as the time of the first assessment time showing statistical significance between d-ATS and placebo. 2 hours post-dose in Double-Blind Treatment Period

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch12.2
Placebo Patch19.0

[back to top]

Permanent Product Measure of Performance (PERMP) Scores Including PREMP-C and PREMP-A From Different Timepoints Post-dose

To assess efficacy of d-ATS compared to placebo as measured by the PERMP-C (number of correct answers) and PERMP-A (number of attempted answers) score. The PERMP is an age-adjusted written math test, of 10 minutes' duration administered at multiple time points. Subjects are given 5 pages of 80 math problems (400 total problems) and are instructed to work at their desks and to complete as many problems as possible in 10 minutes. Performance is measured as the number of problems attempted (PERMP-A) and the number of problems worked correctly (PERMP-C). The scores range from 0-800 with higher scores indicating better performance. (NCT01711021)
Timeframe: 1,2, 3, 4.5,6,7,9,10 and 12 hours post-dose from double-blind treatment period

,
Interventionscore on a scale (Least Squares Mean)
PERMP-C at 1 hourPERMP-C at 2 hoursPERMP-C at 3 hoursPERMP-C at 4.5 hoursPERMP-C at 6 hoursPERMP-C at 7 hoursPERMP-C at 9 hoursPERMP-C at 10 hoursPERMP-C at 12 hoursPERMP-A at 1 hourPERMP-A at 2 hoursPERMP-A at 3 hoursPERMP-A at 4.5 hoursPERMP-A at 6 hoursPERMP-A at 7 hoursPERMP-A at 9 hoursPERMP-A at 10 hoursPERMP-A at 12 hours
d-Amphetamine Transdermal Patch124.0139.8141.2141.5139.7139.7139.0132.4135.3126.6142.7144.0144.0142.0142.3141.7134.7137.4
Placebo Patch113.1103.893.797.994.396.2102.998.996.4116.3106.397.4100.996.898.9106.8102.1100.1

[back to top]

Mean Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score During the Double-Blind Treatment Period

The SKAMP total score comprises all 13 items. The SKAMP was designed for independent observers to rate 13 items representing 2 factors of classroom behavior: attention (SKAMP-A) and deportment (SKAMP-D), as well as quality of work. Items are specific to place (classroom setting) & time (during a typical classroom period), & the scale is used to assess multiple ratings taken within a day. The SKAMP-D subscale evaluates deportment, including interacting with other children, interacting with adults, remaining quiet according to classroom rules, & staying seated according to classroom rules. The SKAMP-A subscale is a measure of attention & evaluates getting started on assignments, sticking with tasks, attending to an activity, and making activity transitions. The SKAMP quality of work subscale includes 3 items: completing assigned work, performing work accurately, and being careful and neat while writing or drawing. Scores range from 0-78 with higher scores indicating worse impairment. (NCT01711021)
Timeframe: Mean SKAMP Total Score of SKAMP Total Scores from 9 different time points including (1, 2, 3, 4.5, 6, 7, 9, 10, 12 hours post-dose)

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch12.81
Placebo Patch18.67

[back to top]

Change in the Clinician-rated Scale of ADHD Symptoms Based on DSM-IV-TR Criteria (ADHD-RS-IV).

"The ADHD-RS-IV is based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria to assess efficacy of d-ATS compared to placebo. The ADHD-RS-IV scale was developed to measure the behaviors of children with ADHD, and it consists of 18 items designed to reflect current symptomatology of ADHD based on DSM-IV criteria. Each item is scored from a range of 0 (reflecting no symptoms) to 3 (reflecting severe symptoms) with total scores ranging from 0 to 54.~Note: Week 6 is the first week of the double-blind treatment period, week 7 is the second week of the double-blind treatment period." (NCT01711021)
Timeframe: Averaged from week 6 and week 7 results during the Double-Blind Cross-Over treatment period.

Interventionscore on a scale (Least Squares Mean)
d-Amphetamine Transdermal Patch-23.4
Placebo Patch-10.3

[back to top]

Dopamine D2/D3 Receptor Binding as Measured During the PET Scan After Amphetamine Administration

Use PET and [11C]raclopride to explore Dopamine D2/D3 receptor binding potential (BPND) in striatal regions of interest in eating disorder subtypes after amphetamine administration. The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. (NCT02020408)
Timeframe: 90 min PET scan

,,
Interventionbinding potential (BPND) (Mean)
[11C]raclopride BPND anteroventral striatum[11C]raclopride BPND post dorsal caudate[11C]raclopride BPND anterior putamen[11C]raclopride BPND posterior putamen[11C]raclopride BPND predorsal caudate
[11C]Raclopride Binding Potential Control Women2.091.692.712.532.48
[11C]Raclopride Binding Potential in REC AN2.011.622.652.462.40
[11C]Raclopride Binding Potential in REC ANBN1.941.692.602.472.47

[back to top]

5-HT Transporter Binding as Measured During the PET Scan

"Use PET and [11C]DASB to explore 5-HTT receptor binding potential midbrain and striatal regions of interest in eating disorder subtypes.~The Binding Potential (BP) was calculated as BP Non Displaceable (ND) = (VT/VND) -1. [VT = distribution volume in tissue; VND = non-displaceable distribution volume]. The binding of the 5-HTT on PET presumably reflects 5-HTT density and/or affinity." (NCT02020408)
Timeframe: 90 minute PET scan

,,,
Interventionbinding potential (BPND) (Mean)
[11C]DASB BPND anteroventral striatum[11C]DASB BPND post dorsal caudate[11C]DASB BPND posterior putamen[11C]DASB BPND predorsal caudate[11C]DASB BPND anterior putamen[11C]DASB BPND midbrain
[11C]DASB Binding Potential Control Women1.680.441.361.081.702.21
[11C]DASB Binding Potential in REC AN1.540.351.270.991.592.06
[11C]DASB Binding Potential in REC ANBN1.460.391.170.991.491.98
[11C]DASB Binding Potential in REC BN1.600.371.320.981.572.17

[back to top]

Cognitive Task Performance

Response time to words (gambling, alcohol, positive affect, negative affect) as a percentage of neutral categorized words (parts of a building). This provides an index of the relative salience of stimuli from these four categories against a baseline of reaction to words with no clinical relevance or emotional valence. Smaller scores indicate faster relative response time to the test stimuli vs. neutral stimuli (i.e., greater salience) (NCT02203786)
Timeframe: At key points during testing: immediately after the slot machine, at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration)

,,,
Interventionpercentage of neutral categorized words (Mean)
post-slots-GAM words under drugpost-slots-ALC words under drugpost-slots POS words under drugpost-slots NEG words under drugpost-slots GAM words under placebopost-slots ALC words under placebopost-slots POS words under placebopost-slots NEG words under placebopeak AMPH GAM words under drugpeak AMPH ALC words under drugpeak AMPH POS words under drugpeak AMPH NEG words under drugpeak AMPH GAM words under placebopeak AMPH ALC words under placebopeak AMPH POS words under placebopeak AMPH NEG words under placebo
Fluphenazine - Controls91.093.188.387.992.193.386.884.797.0100.396.398.796.997.595.196.7
Fluphenazine - Pathological Gamblers94.098.195.396.595.099.094.997.295.899.598.799.497.999.997.7100.0
Haloperidol - Controls94.896.593.789.697.297.093.792.398.199.197.296.896.8100.297.898.1
Haloperidol - Pathological Gamblers91.695.591.389.191.694.892.793.096.7101.298.299.595.099.998.499.0

[back to top]

Speed of Play on Slot Machine Game

Number of individual spins in a 15-minute slot machine game. Each spin corresponds to one wager. (NCT02203786)
Timeframe: 15-minutes

,,,
Interventionindividual spins/15-minutes (Mean)
Spins/15-minutes under DrugSpins/15-minutes under Placebo
Fluphenazine - Controls71.866.7
Fluphenazine - Pathological Gamblers78.568.4
Haloperidol - Controls66.472.2
Haloperidol - Pathological Gamblers76.988.6

[back to top]

Betting Behaviour in Laboratory-based Slot Machine Game

Risk taking was operationally defined as credits wagered per spin (mean computed for total spins) (NCT02203786)
Timeframe: 1x per test session (total of 4 test sessions) for duration of the study: 4 weeks (1 session/week)

,,,
Interventioncredits/spin on slot machine (Mean)
Mean bet under drugMean bet under placebo
Fluphenazine - Controls14.412.2
Fluphenazine - Pathological Gamblers16.016.1
Haloperidol - Controls11.69.5
Haloperidol - Pathological Gamblers12.810.4

[back to top]

Winnings on Slot Machine Upon Completion of Game

Credits (NCT02203786)
Timeframe: 15-minutes

,,,
Interventioncredits (Mean)
Winnings (Final Credit Tally) under drugWinnings (Final Credit Tally) under Placebo
Fluphenazine - Controls544.3215
Fluphenazine - Pathological Gamblers277.8140.8
Haloperidol - Controls449.1339.2
Haloperidol - Pathological Gamblers239562.4

[back to top]

Diastolic Blood Pressure (DBP)

Measure changes from baseline, especially physiologic reactivity to the slot machine and amphetamine. (NCT02203786)
Timeframe: At key points in testing: immediately after the slot machine game (change from session baseline), and at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration)(change from session baseline).

,,,
Interventionmm Hg (Mean)
Drug-Change in DBP pre-to-post slot machinePlacebo-Change in DBP pre-to-post slot machineDrug-Change in DBP pre-amphetamine to peak amphPlacebo-Change in DBP pre-amphetamine to peak amp
Fluphenazine - Controls23.61932.736.3
Fluphenazine - Pathological Gamblers2221.632.135.2
Haloperidol - Controls15.119.128.526.6
Haloperidol - Pathological Gamblers20.222.527.233.6

[back to top]

Subjective Reinforcement Self-report Scales

Self-reported Confidence to Refrain from Gambling (0 - 10) was assessed at test session baseline, before the slot machine and after the slot machine (Phase 1); and before amphetamine and at peak amphetamine (Phase 2). The maximum score (10) denotes complete confidence to refrain from gambling (i.e., NO urge or compulsion to gamble); the minimum score (0) denotes complete lack of confidence to refrain from gambling (i.e., overwhelming urge to gamble). Scores between 10 and 0 denote intermediate confidence to refrain from gambling with LOWER scores denoting less confidence to refrain from gambling -- i.e., GREATER urge or compulsive motivation to gamble. Scores shown are based on single item visual analogue ratings 0-10 from each participant at the specified time point. The mean (SD) of these single item ratings is presented for each sub-group. (NCT02203786)
Timeframe: At key points in testing: immediately after the slot machine game, and at expected peak subjective-behavioral effects for amphetamine (90-minutes post-capsule administration).

,,,
Interventionunits on a scale (Mean)
Drug - Confidence not to gamble after slot machinePlacebo - Confidence not to gamble after slot machDrug - Confidence not to gamble at peak amphetaminPlac -Confidence not to gamble at peak amphetamine
Fluphenazine - Controls9.38.29.89.3
Fluphenazine - Pathological Gamblers4.84.86.45.7
Haloperidol - Controls9.599.89.4
Haloperidol - Pathological Gamblers4.84.25.25.5

[back to top]

Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent)

"The Behavior Rating Inventory of Executive Function - Parent Form (BRIEF-Parent) is a 75-item checklist with a large normative sample, internal consistency, test-retest reliability, inter-rater reliability, and external and concurrent validity, divided into nine empirically and theoretically derived and T-scored subscales. The Emotional Control subscale measures the impact of executive function problems on emotional expression and assesses a child's ability to modulate or control his or her emotional responses. It is a 10-item subscale, and each item is scored Never, Sometimes, or Often. Raw scores for all scales are computed with Software Portfolio (BRIEF-SP), which provides a raw score and T score (based on child's age) for each scale. Higher scores represent more greater emotional dysregulation." (NCT02204410)
Timeframe: Baseline and 12 Weeks

Interventionunits on a scale (Mean)
Emotional Control Subscale T Score BaselineEmotional Control Subscale T Score Endpoint
Omega-3 Fatty Acids and Stimulant Treatment65.358.4

[back to top]

Clinical Global Impression (CGI) Improvement for Deficient Emotional Self-Regulation (DESR)

"The Clinical Global Impression (CGI) is a clinician rated measure of illness severity, improvement, and efficacy of treatment (collected at all study visits). We examined the CGI Improvement specifically. The CGI Improvement for Deficient Emotional Self-Regulation (DESR) was reported at baseline and completion. The CGI-I is a 7 point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. It is rated as:~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Much worse~Very much worse" (NCT02204410)
Timeframe: Baseline and 12 Weeks

Interventionunits on a scale (Mean)
CGI Improvement for DESR BaselineCGI Improvement for DESR Endpoint
Omega-3 Fatty Acids and Stimulant Treatment4.63.0

[back to top]

Percent Change in Binding Potential of Dopamine Release During PET Scan Post Amphetamine Administration

Percent change in binding potential of dopamine release during PET scan post amphetamine administration.Binding potential (BP) is the PET neuroimaging outcome measure that is computed as a proxy for availability of dopamine D2/3 receptors in a given region-of-interest. (NCT02348385)
Timeframe: After 2 PET Scans (1 day)

Interventionpercentage change in binding potential (Mean)
Male Healthy Tobacco Smokers14
Male Healthy Nonsmokers11.2
Female Healthy Tobacco Smokers1.9
Female Healthy Nonsmokers9.3

[back to top]

The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative

The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Lile et al., 2016) in which subjects made 9 choices between each available cocaine dose and money (US$6.00). Reinforcing effects are measured for each cocaine dose during both d-amphetamine and placebo maintenance. (NCT02383043)
Timeframe: 9 choice trials per cocaine dose level with each trial separated by 30 minutes

,,
Interventioncocaine choices (Mean)
Placebo Cocaine3 mg/70 kg Cocaine10 mg/70 kg Cocaine30 mg/70kg Cocaine
30 mg d-Amphetamine0.060.881.884.69
60 mg d-Amphetamine0.750.561.505.19
Placebo Treatment0.942.505.136.00

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 150 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm30.8321.3340.7520.4612.58
ALC Placebo Arm4.632.424.292.135.04
AMP Arm19.7939.511.2516.3344.08
AMP Placebo Arm5.836.748.092.872.87
THC Arm18.6311.7117.7914.759.38
THC Placebo Arm4.634.966.421.966.21

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 180 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm22.219.0429.514.137.0
ALC Placebo Arm2.081.754.291.254.04
AMP Arm16.1331.0811.5411.6738.38
AMP Placebo Arm3.52.544.251.632.46
THC Arm15.677.3316.1311.7910.04
THC Placebo Arm2.544.04.631.045.04

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 210 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm12.887.3322.719.214.54
ALC Placebo Arm0.960.251.290.833.83
AMP Arm11.0818.388.546.2532.5
AMP Placebo Arm2.171.967.460.332.25
THC Arm5.794.886.834.968.79
THC Placebo Arm1.084.384.540.426.17

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm12.8318.6711.718.8313.5
ALC Placebo Arm9.3810.0411.05.53.71
AMP Arm4.7916.084.213.2914.21
AMP Placebo Arm12.179.010.716.965.63
THC Arm11.0811.7512.3810.586.54
THC Placebo Arm4.59.670.833.6711.0

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm76.8345.0843.9650.3824.75
ALC Placebo Arm17.8314.3816.6811.510.0
AMP Arm43.4253.8815.7130.542.17
AMP Placebo Arm21.5816.6317.7112.5410.96
THC Arm38.2528.7525.6331.7517.46
THC Placebo Arm18.6325.2915.7912.9618.96

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 90 Minutes After Drink Administration

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm61.2129.9250.4641.8325.88
ALC Placebo Arm12.7511.3815.337.257.71
AMP Arm34.9255.6716.5427.9250.21
AMP Placebo Arm16.4610.4217.546.836.54
THC Arm31.5420.0823.2529.2116.54
THC Placebo Arm13.1713.2515.967.5812.88

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 150 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 150 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 150 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.54-1.540.79-2.045.460.75
ALC Placebo Arm-0.54-1.25-0.13-0.671.58-0.21
AMP Arm2.292.960.51.75-11.54
AMP Placebo Arm-0.130.130.09-0.430.650.22
THC Arm-0.17-0.960.58-1.292.580.83
THC Placebo Arm-0.08-0.08-0.17-0.420.790.08

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 180 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 180 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 180 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.75-1.290.54-1.53.630.08
ALC Placebo Arm-0.33-1.08-0.04-0.380.71-0.13
AMP Arm1.581.920.461.13-0.461.21
AMP Placebo Arm-0.040.330.04-0.330.210.13
THC Arm-0.21-0.670.54-1.292.130.71
THC Placebo Arm-0.17-0.170.04-0.290.42-0.08

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 210 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 210 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 210 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.71-1.170.33-1.253.170.08
ALC Placebo Arm-0.54-0.791.67-0.380.21-0.17
AMP Arm1.01.380.630.83-0.290.96
AMP Placebo Arm-0.170.130.25-0.17-0.290
THC Arm-0.46-0.880.54-0.831.040.21
THC Placebo Arm0.080.040.04-0.130.13-0.08

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Capsule Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after capsule administration and before drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after capsule administration and before drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm0.25-0.290.33-0.751.290.83
ALC Placebo Arm-0.17-0.670.08-0.920.920.33
AMP Arm-0.17-0.580.13-0.460.580.08
AMP Placebo Arm-0.25-0.580.13-1.171.960.5
THC Arm-0.04-0.710.38-0.792.920.42
THC Placebo Arm0.540.33-0.170.250.420.42

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 30 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 30 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 30 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm1.921.382.63-0.883.713.42
ALC Placebo Arm-0.33-1.170.29-0.961.540.29
AMP Arm2.883.711.131.63-13.21
AMP Placebo Arm000.33-0.832.250.42
THC Arm0.17-0.541.54-1.382.962.04
THC Placebo Arm0.710.880.130.041.130.96

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 90 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects. The change in ARCI was assessed by the difference in measurements between baseline and 90 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 90 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm0.29-0.381.79-2.546.212.25
ALC Placebo Arm-0.58-1.290.29-1.131.920.13
AMP Arm2.963.671.082.17-1.212.63
AMP Placebo Arm-0.33-0.29-0.04-1.292.670.42
THC Arm0-0.831.42-1.713.542.04
THC Placebo Arm-0.08-0.130.08-0.671.580.29

[back to top]

Change in General Drug Effects (Drug Effects Questionnaire) at 120 Minutes After Drink Administraion

Drug effects will be measured using the Drug Effects Questionnaire (Fischman & Foltin, 1991). The DEQ included 5 subscales; feeling, liking, and disliking the drug effect, feeling high, and wanting more of the drug. Each subscale ranged from 1(Not at all) to 100(Very much). The change in DFQ was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration.

,,,,,
Interventionunits on a scale (Mean)
DEQ FeelDEQ LikeDEQ DislikeDEQ HighDEQ More
ALC Arm43.9223.7944.9229.3817.5
ALC Placebo Arm7.964.8311.085.086.54
AMP Arm27.0843.7511.9218.8845.38
AMP Placebo Arm11.927.0413.385.043.13
THC Arm24.081819.6321.969.92
THC Placebo Arm7.888.678.884.839.88

[back to top]

Change in Specific Drug Effects (Addiction Research Center Inventory) at 120 Minutes After Drink Administration

Specific drug effects will be measured using the Addiction Research Center Inventory (Martin et al. 1971). The ARCI measures effects specific to drug classes, including the effects of AMP-like drugs (A scale, 0 to 11), morphine and benzedrine like drugs (MBG scale, 0 to 14), lysergic acid-like drugs (LSD scale, 0 to 14), benzedrine-like drugs (BG scale, 0 to 13), pentobarbital-chlorpromazine and ALC-like drugs (PCAG scale, 0 to 15), and cannabis-like drugs (M scale, 0 to 12). We used this questionnaire as a manipulation check to ensure that the drugs produced their typical drug-specific effects in this study. For example, zero value of A sacle would be minimum report of amphetamine-like drug effects, and 11 would be maximum report of amphetamine-like effects.The change in ARCI was assessed by the difference in measurements between baseline and 120 minutes after drink administration. Baseline was measure 15 minutes prior to capsule administration. (NCT02485158)
Timeframe: Measured 15 minutes prior to capsule administration and 120 minutes after drink administration

,,,,,
Interventionunits on a scale (Mean)
ARC AARC MBGARC LSDARC BGARC PCAGARC M
ALC Arm-0.33-1.130.79-2.045.461.08
ALC Placebo Arm-0.71-1.290.04-0.831.63-0.04
AMP Arm2.173.330.381.67-1.081.83
AMP Placebo Arm-0.17-0.125-0.13-11.710.25
THC Arm-0.08-0.961-1.542.881.42
THC Placebo Arm-0.04-0.08-0.08-0.381.080.17

[back to top]

Percent Change in Aphasia Quotient as Assessed by the Western Aphasia Battery

The score on the Aphasia Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported. (NCT02514044)
Timeframe: immediately before the treatment, immediately after the treatment

Interventionpercent change in aphasia quotient (Mean)
Dexedrine+tDCS+Speech Therapy7.9
Placebo+tDCS+Speech Therapy-.02

[back to top]

Percent Change in Language Quotient as Assessed by the Western Aphasia Battery

The score on the Language Quotient of the Western Aphasia Battery ranges between 0-100. Higher scores indicate better performance. Below, percent change in the score is reported. (NCT02514044)
Timeframe: immediately before the treatment, immediately after the treatment

Interventionpercent change in language quotient (Mean)
Dexedrine+tDCS+Speech Therapy11.02
Placebo+tDCS+Speech Therapy-4.2

[back to top]

Percent Change in Blood Pressure

Non-invasive BP measurements performed by a clinician before and after each experiment. (NCT02514044)
Timeframe: immediately before the treatment, after after the treatment

,
Interventionpercent change in blood pressure (Mean)
Systolic blood pressureDiastolic blood pressure
Dexedrine+tDCS+Speech Therapy1011
Placebo+tDCS+Speech Therapy45

[back to top]

Targeted Cognitive Training (TCT): PositScience, Inc.

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionmsec (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo-2.11329.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine5.91135.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo-50.158101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine-15.11852.647

[back to top]

Prepulse Inhibition (PPI)

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Intervention% inhibition of startle (Mean)
PlaceboAmphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo50.62653.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine50.62645.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo41.16239.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine22.62932.656

[back to top]

MATRICS Consensus Cognitive Battery Performance (MCCB)

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

,,,
Interventionstandardized T-score (Mean)
placeboamphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo57.87056.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine54.47655.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo39.89538.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine31.89533.842

[back to top]

"Change in Subjective Effects as Assessed by Score on Feel Drug, Feel High, Like Drug, and Want More Sub-scales of Drug Effects Questionnaire (DEQ)."

"Participants will complete The Drug Effects Questionnaire during the initial baseline session to determine their subjective stimulant profile. The Dug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: Feel Drug, Feel High, Like Drug, and Want More. All sub-scales are scored on a visual analogue scale (Scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome." (NCT03810703)
Timeframe: End of study (Baseline - time 0 and approximately 4 weeks later)

,,
Interventionscore on a scale (Mean)
FeelLikeDislikeHighMore
Amphetamine 10 mg Arm35.2550.6927.1924.8845.38
Amphetamine 20 mg Arm45.7552.8116.2532.6952.44
Placebo Arm18.8837.4419.0017.5029.19

[back to top]